Certification Under 37 CFR 1.10

I hereby certify that this paper and the documents referred to as attached therein are being deposited with the United States Postal Service on the date shown below in an envelope "Express Mail Post Office to Addressee" mailing Label Number **EJ652270716US** addressed to the: Assistant Commissioner for Patents, Washington, D.C. 20231.

Denise Ortega

Name

September 27, 2001

Date

Denise Ortega

Signature

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Jan Zavada et al.

Serial No.:

Filed :

For : MN Gene and Protein

Group:

Group Art Unit:

Examiner:

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

As part of the accompanying request for filing of a divisional application under 37 CFR 1.53(b)(1), before calculating the filing fee and preliminary to the examination of the above-identified application, please amend the application as indicated below.

IN THE SPECIFICATION

Please make amendments to the Specification as indicated below.

Please replace the paragraph on page 1, lines 4-15 with the following paragraph:

This application is a divisional of U.S. Serial No. 09/178,115 (filed October 23, 1998), which will issue as U.S. Patent No. 6,297,041 on October 2, 2001, which is a continuation-in-part of U.S. Serial No. 08/787,739 (filed January 24, 1997), which issued as U.S. Patent No. 6,027,887 on February 22, 2000, which in turn is a continuation-in-part of the following seven U.S. Serial Nos., all of which were filed on June 7, 1995: U.S. Serial No. 08/485,049, which issued as U.S. Patent 6,204,370 on March 20, 2001, U.S. Serial No. 08/486,756, which issued as U.S. Patent 5,981,711 on November 9, 1999, U.S. Serial No. 08/477,504, which issued as U.S. Patent No. 5,972,353 on October 26, 1999, U.S. Serial No. 08/481,658, which issued as U.S. Patent No. 5,955,075 on September 21, 1999, U.S. Serial No. 08/485,862, which issued as U.S. Patent No. 5,989,838 on November 23, 1999, U.S. Serial No. 08/485,863, which issued as U.S. Patent No. 6,093,858 on July 25, 2000 and U.S. Serial No. 08/487,077, issued as U.S. Patent No. 6,069,242 on May 30, 2000. Those seven

applications are continuations-in-parts of now pending U.S. Serial No. 08/260,190 (filed June 15, 1994), which, in turn, is a continuation-in-part of U.S. Serial No. 08/177,093 (filed December 30, 1993), which issued as U.S. Patent No. 6,051,226 on April 18, 2000, which is in turn a continuation-in-part of U.S. Serial No. 07/964,589 (filed October 21, 1992), which issued as U.S. Patent No. 5,387,676 on February 7, 1995. This application declares priority under 35 USC § 120 from those U.S. applications and patents, and also under 35 USC § 119 from the now abandoned Czechoslovakian patent application PV-709-92 (filed March 11, 1992).

Please replace the paragraph on page 3, lines 12-25 with the following paragraph:

MN/CA IX has a number of properties that distinguish it from other known CA isoenzymes and evince its relevance to oncogenesis. Those properties include its density dependent expression in cell culture, (e.g., HeLa cells), its correlation with the tumorigenic phenotype of somatic cell hybrids between HeLa and normal human fibroblasts, its close association with several human carcinomas and its absence from corresponding normal tissues [e.g., Zavada et al., Int. J. Cancer, 54: 268-274 (1993); Pastorekova et al., Virology, 187: 620-626 (1992); Liao

et al., Am. J. Pathol., 145: 598-609 (1994); Pastorek et al., Oncogene, 9: 2788-2888 (1994); Cote, Women's Health Weekly: News Section, p. 7 (March 30, 1998); Liao et al., Cancer Res., 57: 2827 (1997); Vermylen et al., "Expression of the MN antigen as a biomarker of lung carcinoma and associated precancerous conditions," Proceedings AACR, 39: 334 (1998); McKiernan et al., Cancer Res., 57: 2362 (1997); and Turner et al., Hum. Pathol., 28(6): 740 (1997)]. In addition, the *in vitro* transformation potential of MN/CA IX cDNA has been demonstrated in NIH 3T3 fibroblasts [Pastorek et al., id.].

Please replace the paragraph on page 11, lines 23-26 with the following paragraph:

Identified herein is the location of the MN protein binding site. Also identified are MN oligopeptides that compete for attachment to cells with immobilized MN protein. Such oligopeptides prevent cell-cell adhesion and the formation of intercellular contacts.

Please replace the paragraph on page 14, lines 22-30 with the following paragraph:

A hybridoma that produces a representative MN-specific antibody, the monoclonal antibody M75 (Mab M75), was deposited at the ATCC under Number HB 11128 as indicated above. The M75

antibody was used to discover and identify the MN protein and can be used to identify readily MN antigen in Western blots, in radioimmunoassays and immunohistochemically, for example, in tissue samples that are fresh, frozen, or formalin-, alcohol-, acetone- or otherwise fixed and/or paraffin-embedded and deparaffinized. Another representative MN-specific antibody, Mab MN12, is secreted by the hybridoma MN 12.2.2, which was deposited at the ATCC under the designation HB 11647.

Please replace line 25 on page 17 with the following line:

IPTG - isopropyl-beta-D-thiogalacto-pyranoside

Please replace the paragraph on page 31, lines 7-13 with the following paragraph:

In Zavada et al., id., the isolation of a partial MN cDNA clone of 1397 bp in length was described. A lambda gt11 cDNA library of LMCV-infected HeLa cells was prepared and subjected to immunoscreening with Mab M75 in combination with goat anti-mouse antibodies conjugated with alkaline phosphatase. One positive clone was picked and subcloned into the NotI site of pBluescript KS [Stratagene; La Jolla, CA (USA)] thereby creating pBluescript-MN.

TABLE 1 on page 34, lines 1-33 has been amended as follows:

TABLE 1

Exon-Intron Structure of the Human MN Gene

Exon	Size	Genomic Position**	SEQ ID NO	5'splice acceptor	SEQ ID NO
1	445	*3507-3951	28	AGAAG gtaagt	67
2	30	5126-5155	29	TGGAG gtgaga	68
3	171	5349-5519	30	CAGTC gtgagg	69
4	143	5651-5793	31	CCGAG gtgagc	70
5	93	5883-5975	32	TGGAG gtacca	71
6	67	7376-7442	33	GGAAG gtcagt	72
7	158	8777-8934	34	AGCAG gtgggc	73
8	145	9447-9591	35	GCCAG gtacag	74
9	27	9706-9732	36	TGCTG gtgagt	75
10	82	10350-70431	37	CACAG gtatta	76
11	191	10562-10752	38	ATAAT end	

Intron	Size	Genomic Position **	SEQ ID NO	3'splice acceptor	SEQ ID NO
1	1174	3952-5125	39	atacag GGGAT	77
2	193	5156-5348	40	ccccag GCGAC	78
3	131	5520-5650	41	acgcag TGCAA	79
4	89	5794-5882	42	tttcag ATCCA	80
5	1400	5976-7375	43	ccccag GAGGG	81
6	1334	7443-8776	44	tcacag GCTCA	82
7	512	8935-9446	45	ccctag CTCCA	83
8	114	9592-9705	46	ctccag TCCAG	84
9	617	9733-10349	47	tcgcag GTGACA	85
10	130	10432-10561	48	acacag AAGGG	86

** positions are related to nt numbering in whole genomic sequence including the 5' flanking region [Figure 2A-F]

* number corresponds to transcription initiation site determined below by RNase protection assay

Please replace line 26 on page 45 with the following line:

EMSA Supershift Analysis

Please replace the paragraph on page 71, lines 27-32 with the following paragraph:

MAb M75. Monoclonal antibody M75 (MAb M75) is produced by mouse lymphocytic hybridoma VU-M75, which was initially deposited in the Collection of Hybridomas at the Institute of Virology, Slovak Academy of Sciences (Bratislava, Slovakia) and was deposited under ATCC Designation HB 11128 on September 17, 1992 at the American Type Culture Collection (ATCC). The production of hybridoma VU-M75 is described in Zavada et al., WO 93/18152.

Please replace the paragraph on page 78, lines 13-18 with the following paragraph:

The M75 MAb (or, for example, as a single chain antibody, or as its variable region) is exemplary of such a MN-specific antibody. Example 5 discloses heptapeptides (SEQ ID NOS: 107-109) that bind to the enzymatic center of the CA domain of the MN protein and, selected peptides or proteins comprising such heptapeptides would also be expected to bind to a binding site on the extracellular domain of the MN protein.

Please replace the paragraph on page 81, lines 7-15 with the following paragraph:

MN proteins and/or polypeptides may be synthesized or prepared recombinantly or otherwise biologically, to comprise one or more amino acid sequences corresponding to one or more epitopes of the MN proteins either in monomeric or multimeric form. Those proteins and/or polypeptides may then be incorporated into vaccines capable of inducing protective immunity. Techniques for enhancing the antigenicity of such polypeptides include incorporation into a multimeric structure, binding to a highly immunogenic protein carrier, for example, keyhole limpet hemocyanin (KLH), or diphtheria toxoid, and administration in combination with adjuvants or any other enhancers of immune response.

Please replace the paragraph on page 98, lines 24-30 with the following paragraph:

The MN protein is a candidate for being the product of the critical oncogene; its expression in the hybrids has been shown to correlate with their tumorigenicity [e.g., Zavada et al. (1993), supra]. The present results indicate that additional mechanisms might exist, which are able to "heal" a cancerous cell. Understanding the molecular mechanisms of action of MN

protein in normal and in tumor cells and elucidating how the reversion works may provide new approaches to cancer therapy.

Please insert the following SEQUENCE LISTING at the end of the Specification on page 117 beginning a new page

SEQUENCE LISTING

<110> Zavada, Jan
Pastorekova, Silvia
Pastorek, Jaromir

<120> MN Gene and Protein

<130> D-0021.5B-2

<140>
<141>

<150> 09/178,115
<151> 1998-10-23

<160> 116

<170> PatentIn Ver. 2.1

<210> 1
<211> 1522
<212> DNA
<213> HUMAN

<220>
<221> CDS
<222> (13)..(1389)

<220>
<221> mat_peptide
<222> (124)..(1389)

<400> 1

```
acagtcagcc gc atg gct ccc ctg tgc ccc agc ccc tgg ctc cct ctg ttg 51
              Met Ala Pro Leu Cys Pro Ser Pro Trp Leu Pro Leu Leu
                        -35                 -30                 -25

atc ccg gcc cct gct cca ggc ctc act gtg caa ctg ctg ctg tca ctg   99
Ile Pro Ala Pro Ala Pro Gly Leu Thr Val Gln Leu Leu Leu Ser Leu
                -20                 -15                 -10

ctg ctt ctg atg cct gtc cat ccc cag agg ttg ccc cgg atg cag gag   147
Leu Leu Leu Met Pro Val His Pro Gln Arg Leu Pro Arg Met Gln Glu
            -5                -1   1                   5

gat tcc ccc ttg gga gga ggc tct tct ggg gaa gat gac cca ctg ggc   195
Asp Ser Pro Leu Gly Gly Gly Ser Ser Gly Glu Asp Asp Pro Leu Gly
     10                  15                  20

gag gag gat ctg ccc agt gaa gag gat tca ccc aga gag gag gat cca   243
Glu Glu Asp Leu Pro Ser Glu Glu Asp Ser Pro Arg Glu Glu Asp Pro
 25                  30                  35                  40

ccc gga gag gag gat cta cct gga gag gag gat cta cct gga gag gag   291
Pro Gly Glu Glu Asp Leu Pro Gly Glu Glu Asp Leu Pro Gly Glu Glu
                 45                  50                  55

gat cta cct gaa gtt aag cct aaa tca gaa gaa gag ggc tcc ctg aag   339
Asp Leu Pro Glu Val Lys Pro Lys Ser Glu Glu Glu Gly Ser Leu Lys
            60                  65                  70

tta gag gat cta cct act gtt gag gct cct gga gat cct caa gaa ccc   387
Leu Glu Asp Leu Pro Thr Val Glu Ala Pro Gly Asp Pro Gln Glu Pro
         75                  80                  85

cag aat aat gcc cac agg gac aaa gaa ggg gat gac cag agt cat tgg   435
Gln Asn Asn Ala His Arg Asp Lys Glu Gly Asp Asp Gln Ser His Trp
     90                  95                  100

cgc tat gga ggc gac ccg ccc tgg ccc cgg gtg tcc cca gcc tgc gcg   483
Arg Tyr Gly Gly Asp Pro Pro Trp Pro Arg Val Ser Pro Ala Cys Ala
105                 110                 115                 120

ggc cgc ttc cag tcc ccg gtg gat atc cgc ccc cag ctc gcc gcc ttc   531
Gly Arg Phe Gln Ser Pro Val Asp Ile Arg Pro Gln Leu Ala Ala Phe
                125                 130                 135
```

```
tgc ccg gcc ctg cgc ccc ctg gaa ctc ctg ggc ttc cag ctc ccg ccg   579
Cys Pro Ala Leu Arg Pro Leu Glu Leu Leu Gly Phe Gln Leu Pro Pro
            140                 145                 150

ctc cca gaa ctg cgc ctg cgc aac aat ggc cac agt gtg caa ctg acc   627
Leu Pro Glu Leu Arg Leu Arg Asn Asn Gly His Ser Val Gln Leu Thr
        155                 160                 165

ctg cct cct ggg cta gag atg gct ctg ggt ccc ggg cgg gag tac cgg   675
Leu Pro Pro Gly Leu Glu Met Ala Leu Gly Pro Gly Arg Glu Tyr Arg
    170                 175                 180

gct ctg cag ctg cat ctg cac tgg ggg gct gca ggt cgt ccg ggc tcg   723
Ala Leu Gln Leu His Leu His Trp Gly Ala Ala Gly Arg Pro Gly Ser
185                 190                 195                 200

gag cac act gtg gaa ggc cac cgt ttc cct gcc gag atc cac gtg gtt   771
Glu His Thr Val Glu Gly His Arg Phe Pro Ala Glu Ile His Val Val
                205                 210                 215

cac ctc agc acc gcc ttt gcc aga gtt gac gag gcc ttg ggg cgc ccg   819
His Leu Ser Thr Ala Phe Ala Arg Val Asp Glu Ala Leu Gly Arg Pro
            220                 225                 230

gga ggc ctg gcc gtg ttg gcc gcc ttt ctg gag gag ggc ccg gaa gaa   867
Gly Gly Leu Ala Val Leu Ala Ala Phe Leu Glu Glu Gly Pro Glu Glu
        235                 240                 245

aac agt gcc tat gag cag ttg ctg tct cgc ttg gaa gaa atc gct gag   915
Asn Ser Ala Tyr Glu Gln Leu Leu Ser Arg Leu Glu Glu Ile Ala Glu
    250                 255                 260

gaa ggc tca gag act cag gtc cca gga ctg gac ata tct gca ctc ctg   963
Glu Gly Ser Glu Thr Gln Val Pro Gly Leu Asp Ile Ser Ala Leu Leu
265                 270                 275                 280

ccc tct gac ttc agc cgc tac ttc caa tat gag ggg tct ctg act aca   1011
Pro Ser Asp Phe Ser Arg Tyr Phe Gln Tyr Glu Gly Ser Leu Thr Thr
                285                 290                 295

ccg ccc tgt gcc cag ggt gtc atc tgg act gtg ttt aac cag aca gtg   1059
Pro Pro Cys Ala Gln Gly Val Ile Trp Thr Val Phe Asn Gln Thr Val
            300                 305                 310
```

```
atg ctg agt gct aag cag ctc cac acc ctc tct gac acc ctg tgg gga   1107
Met Leu Ser Ala Lys Gln Leu His Thr Leu Ser Asp Thr Leu Trp Gly
        315                 320                 325

cct ggt gac tct cgg cta cag ctg aac ttc cga gcg acg cag cct ttg   1155
Pro Gly Asp Ser Arg Leu Gln Leu Asn Phe Arg Ala Thr Gln Pro Leu
    330                 335                 340

aat ggg cga gtg att gag gcc tcc ttc cct gct gga gtg gac agc agt   1203
Asn Gly Arg Val Ile Glu Ala Ser Phe Pro Ala Gly Val Asp Ser Ser
345                 350                 355                 360

cct cgg gct gct gag cca gtc cag ctg aat tcc tgc ctg gct gct ggt   1251
Pro Arg Ala Ala Glu Pro Val Gln Leu Asn Ser Cys Leu Ala Ala Gly
                365                 370                 375

gac atc cta gcc ctg gtt ttt ggc ctc ctt ttt gct gtc acc agc gtc   1299
Asp Ile Leu Ala Leu Val Phe Gly Leu Leu Phe Ala Val Thr Ser Val
            380                 385                 390

gcg ttc ctt gtg cag atg aga agg cag cac aga agg gga acc aaa ggg   1347
Ala Phe Leu Val Gln Met Arg Arg Gln His Arg Arg Gly Thr Lys Gly
        395                 400                 405

ggt gtg agc tac cgc cca gca gag gta gcc gag act gga gcc           1389
Gly Val Ser Tyr Arg Pro Ala Glu Val Ala Glu Thr Gly Ala
    410                 415                 420

tagaggctgg atcttggaga atgtgagaag ccagccagag gcatctgagg gggagccggt 1449

aactgtcctg tcctgctcat tatgccactt ccttttaact gccaagaaat tttttaaaat 1509

aaatatttat aat                                                    1522
```

<210> 2
<211> 459
<212> PRT
<213> HUMAN

<400> 2

```
Met Ala Pro Leu Cys Pro Ser Pro Trp Leu Pro Leu Leu Ile Pro Ala
        -35                 -30                 -25

Pro Ala Pro Gly Leu Thr Val Gln Leu Leu Leu Ser Leu Leu Leu Leu
    -20                 -15                 -10
```

```
Met Pro Val His Pro Gln Arg Leu Pro Arg Met Gln Glu Asp Ser Pro
 -5              -1   1               5                  10

Leu Gly Gly Gly Ser Ser Gly Glu Asp Asp Pro Leu Gly Glu Glu Asp
             15                  20                  25

Leu Pro Ser Glu Glu Asp Ser Pro Arg Glu Glu Asp Pro Pro Gly Glu
         30                  35                  40

Glu Asp Leu Pro Gly Glu Glu Asp Leu Pro Gly Glu Glu Asp Leu Pro
     45                  50                  55

Glu Val Lys Pro Lys Ser Glu Glu Glu Gly Ser Leu Lys Leu Glu Asp
 60                  65                  70                  75

Leu Pro Thr Val Glu Ala Pro Gly Asp Pro Gln Glu Pro Gln Asn Asn
                 80                  85                  90

Ala His Arg Asp Lys Glu Gly Asp Asp Gln Ser His Trp Arg Tyr Gly
             95                  100                 105

Gly Asp Pro Pro Trp Pro Arg Val Ser Pro Ala Cys Ala Gly Arg Phe
        110                 115                 120

Gln Ser Pro Val Asp Ile Arg Pro Gln Leu Ala Ala Phe Cys Pro Ala
    125                 130                 135

Leu Arg Pro Leu Glu Leu Leu Gly Phe Gln Leu Pro Pro Leu Pro Glu
140                 145                 150                 155

Leu Arg Leu Arg Asn Asn Gly His Ser Val Gln Leu Thr Leu Pro Pro
                160                 165                 170

Gly Leu Glu Met Ala Leu Gly Pro Gly Arg Glu Tyr Arg Ala Leu Gln
            175                 180                 185

Leu His Leu His Trp Gly Ala Ala Gly Arg Pro Gly Ser Glu His Thr
        190                 195                 200

Val Glu Gly His Arg Phe Pro Ala Glu Ile His Val Val His Leu Ser
    205                 210                 215

Thr Ala Phe Ala Arg Val Asp Glu Ala Leu Gly Arg Pro Gly Gly Leu
220                 225                 230                 235
```

Ala Val Leu Ala Ala Phe Leu Glu Glu Gly Pro Glu Glu Asn Ser Ala
240 245 250

Tyr Glu Gln Leu Leu Ser Arg Leu Glu Glu Ile Ala Glu Glu Gly Ser
255 260 265

Glu Thr Gln Val Pro Gly Leu Asp Ile Ser Ala Leu Leu Pro Ser Asp
270 275 280

Phe Ser Arg Tyr Phe Gln Tyr Glu Gly Ser Leu Thr Thr Pro Pro Cys
285 290 295

Ala Gln Gly Val Ile Trp Thr Val Phe Asn Gln Thr Val Met Leu Ser
300 305 310 315

Ala Lys Gln Leu His Thr Leu Ser Asp Thr Leu Trp Gly Pro Gly Asp
320 325 330

Ser Arg Leu Gln Leu Asn Phe Arg Ala Thr Gln Pro Leu Asn Gly Arg
335 340 345

Val Ile Glu Ala Ser Phe Pro Ala Gly Val Asp Ser Ser Pro Arg Ala
350 355 360

Ala Glu Pro Val Gln Leu Asn Ser Cys Leu Ala Ala Gly Asp Ile Leu
365 370 375

Ala Leu Val Phe Gly Leu Leu Phe Ala Val Thr Ser Val Ala Phe Leu
380 385 390 395

Val Gln Met Arg Arg Gln His Arg Arg Gly Thr Lys Gly Gly Val Ser
400 405 410

Tyr Arg Pro Ala Glu Val Ala Glu Thr Gly Ala
415 420

<210> 3
<211> 29
<212> DNA
<213> HUMAN

<400> 3
cgcccagtgg gtcatcttcc ccagaagag 29

<210> 4
<211> 19
<212> DNA
<213> HUMAN

<400> 4
ggaatcctcc tgcatccgg 19

<210> 5
<211> 10898
<212> DNA
<213> HUMAN

<220>
<221> gene
<222> (1)..(10898)
<223> full-length MN genomic sequence

<220>
<221> unsure of base at position 1974
<222> (1974)
<223> unsure of base at position 1974, which is in the 5' region flanking the transcription initiation site (3507) as determined by RNase protection assay.

<400> 5
ggatcctgtt gactcgtgac cttaccccca accctgtgct ctctgaaaca tgagctgtgt 60
ccactcaggg ttaaatggat taagggcggt gcaagatgtg ctttgttaaa cagatgcttg 120
aaggcagcat gctcgttaag agtcatcacc aatccctaat ctcaagtaat cagggacaca 180
aacactgcgg aaggccgcag ggtcctctgc ctaggaaaac cagagacctt tgttcacttg 240
tttatctgac cttccctcca ctattgtcca tgaccctgcc aaatcccccc ctgtgagaaa 300
cacccaagaa ttatcaataa aaaaataaat ttaaaaaaaa aatacaaaaa aaaaaaaaaa 360
aaaaaaaaaa gacttacgaa tagttattga taaatgaata gctattggta aagccaagta 420
aatgatcata ttcaaaacca gacggccatc atcacagctc aagtctacct gatttgatct 480
ctttatcatt gtcattcttt ggattcacta gattagtcat catcctcaaa attctccccc 540
aagttctaat tacgttccaa acatttaggg gttacatgaa gcttgaacct actaccttct 600
ttgcttttga gccatgagtt gtaggaatga tgagtttaca ccttacatgc tggggattaa 660
tttaaacttt acctctaagt cagttgggta gcctttggct tatttttgta gctaattttg 720
tagttaatgg atgcactgtg aatcttgcta tgatagtttt cctccacact ttgccactag 780
gggtaggtag gtactcagtt ttcagtaatt gcttacctaa gaccctaagc cctatttctc 840
ttgtactggc ctttatctgt aatatgggca tatttaatac aatataattt ttggagtttt 900
tttgtttgtt tgtttgtttg tttttttgag acggagtctt gcatctgtca tgcccaggct 960
ggagtagcag tggtgccatc tcggctcact gcaagctcca cctcccgagt tcacgccatt 1020
ttcctgcctc agcctcccga gtagctggga ctacaggcgc ccgccaccat gcccggctaa 1080
ttttttgtat ttttggtaga gacggggttt caccgtgtta gccagaatgg tctcgatctc 1140

ctgacttcgt gatccacccg cctcggcctc ccaaagttct gggattacag gtgtgagcca 1200
ccgcacctgg ccaatttttt gagtctttta aagtaaaaat atgtcttgta agctggtaac 1260
tatggtacat ttccttttat taatgtggtg ctgacggtca tataggttct tttgagtttg 1320
gcatgcatat gctacttttt gcagtccttt cattacattt ttctctcttc atttgaagag 1380
catgttatat cttttagctt cacttggctt aaaaggttct ctcattagcc taacacagtg 1440
tcattgttgg taccacttgg atcataagtg gaaaaacagt caagaaattg cacagtaata 1500
cttgtttgta agagggatga ttcaggtgaa tctgacacta agaaactccc ctacctgagg 1560
tctgagattc ctctgacatt gctgtatata ggcttttcct ttgacagcct gtgactgcgg 1620
actatttttc ttaagcaaga tatgctaaag ttttgtgagc ctttttccag agagaggtct 1680
catatctgca tcaagtgaga acatataatg tctgcatgtt tccatatttc aggaatgttt 1740
gcttgtgttt tatgctttta tatagacagg gaaacttgtt cctcagtgac ccaaaagagg 1800
tgggaattgt tattggatat catcattggc ccacgctttc tgaccttgga aacaattaag 1860
ggttcataat ctcaattctg tcagaattgg tacaagaaat agctgctatg tttcttgaca 1920
ttccacttgg taggaaataa gaatgtgaaa ctcttcagtt ggtgtgtgtc cctngttttt 1980
ttgcaatttc cttcttactg tgttaaaaaa aagtatgatc ttgctctgag aggtgaggca 2040
ttcttaatca tgatctttaa agatcaataa tataatcctt tcaaggatta tgtctttatt 2100
ataataaaga taatttgtct ttaacagaat caataatata atcccttaaa ggattatatc 2160
tttgctgggc gcagtggctc acacctgtaa tcccagcact ttgggtggcc aaggtggaag 2220
gatcaaattt gcctacttct atattatctt ctaaagcaga attcatctct cttccctcaa 2280
tatgatgata ttgacagggt ttgccctcac tcactagatt gtgagctcct gctcagggca 2340
ggtagcgttt tttgtttttg tttttgtttt tctttttttga gacagggtct tgctctgtca 2400
cccaggccag agtgcaatgg tacagtctca gctcactgca gcctcaaccg cctcggctca 2460
aaccatcatc ccatttcagc ctcctgagta gctgggacta caggcacatg ccattacacc 2520
tggctaattt ttttgtattt ctagtagaga cagggtttgg ccatgttgcc cgggctggtc 2580
tcgaactcct ggactcaagc aatccaccca cctcagcctc ccaaaatgag ggaccgtgtc 2640
ttattcattt ccatgtccct agtccatagc ccagtgctgg acctatggta gtactaaata 2700
aatatttgtt gaatgcaata gtaaatagca tttcagggag caagaactag attaacaaag 2760
gtggtaaaag gtttggagaa aaaaataata gtttaatttg gctagagtat gagggagagt 2820
agtaggagac aagatggaaa ggtctcttgg gcaaggtttt gaaggaagtt ggaagtcaga 2880
agtacacaat gtgcatatcg tggcaggcag tggggagcca atgaaggctt ttgagcagga 2940
gagtaatgtg ttgaaaaata aatataggtt aaacctatca gagcccctct gacacataca 3000
cttgcttttc attcaagctc aagtttgtct cccacatacc cattacttaa ctcaccctcg 3060
ggctccccta gcagcctgcc ctacctcttt acctgcttcc tggtggagtc agggatgtat 3120
acatgagctg ctttccctct cagccagagg acatgggggg ccccagctcc cctgcctttc 3180
cccttctgtg cctggagctg ggaagcaggc cagggttagc tgaggctggc tggcaagcag 3240
ctgggtggtg ccagggagag cctgcatagt gccaggtggt gccttgggtt ccaagctagt 3300
ccatggcccc gataaccttc tgcctgtgca cacacctgcc cctcactcca cccccatcct 3360
agctttggta tgggggagag ggcacagggc cagacaaacc tgtgagactt tggctccatc 3420
tctgcaaaag ggcgctctgt gagtcagcct gctcccctcc aggcttgctc ctcccccacc 3480
cagctctcgt ttccaatgca cgtacagccc gtacacaccg tgtgctggga caccccacag 3540
tcagccgcat ggctcccctg tgccccagcc cctggctccc tctgttgatc ccggcccctg 3600
ctccaggcct cactgtgcaa ctgctgctgt cactgctgct tctggtgcct gtccatcccc 3660
agaggttgcc ccggatgcag gaggattccc ccttgggagg aggctcttct ggggaagatg 3720
acccactggg cgaggaggat ctgcccagtg aagaggattc acccagagag gaggatccac 3780
ccggagagga ggatctacct ggagaggagg atctacctgg agaggaggat ctacctgaag 3840
ttaagcctaa atcagaagaa gagggctccc tgaagttaga ggatctacct actgttgagg 3900

ctcctggaga tcctcaagaa ccccagaata atgcccacag ggacaaagaa ggtaagtggt 3960
catcaatctc caaatccagg ttccaggagg ttcatgactc ccctcccata ccccagccta 4020
ggctctgttc actcagggaa ggaggggaga ctgtactccc cacagaagcc cttccagagg 4080
tcccatacca atatccccat ccccactctc ggaggtagaa agggacagat gtggagagaa 4140
aataaaaagg gtgcaaaagg agagaggtga gctggatgag atgggagaga agggggaggc 4200
tggagaagag aaagggatga gaactgcaga tgagagaaaa aatgtgcaga cagaggaaaa 4260
aaataggtgg agaaggagag tcagagagtt tgaggggaag agaaaaggaa agcttgggag 4320
gtgaagtggg taccagagac aagcaagaag agctggtaga agtcatctca tcttaggcta 4380
caatgaggaa ttgagaccta ggaagaaggg acacagcagg tagagaaacg tggcttcttg 4440
actcccaagc caggaatttg gggaaagggg ttggagacca tacaaggcag agggatgagt 4500
ggggagaaga aagaagggag aaaggaaaga tggtgtactc actcatttgg gactcaggac 4560
tgaagtgccc actcactttt ttttttttt tttttgagac aaactttcac ttttgttgcc 4620
caggctggag tgcaatggcg cgatctcggc tcactgcaac ctccacctcc cgggttcaag 4680
tgattctcct gcctcagcct ctagccaagt agctgcgatt acaggcatgc gccaccacgc 4740
ccggctaatt tttgtatttt tagtagagac ggggtttcgc catgttggtc aggctggtct 4800
cgaactcctg atctcaggtg atccaaccac cctggcctcc caaagtgctg ggattatagg 4860
cgtgagccac agcgcctggc ctgaagcagc cactcacttt tacagaccct aagacaatga 4920
ttgcaagctg gtaggattgc tgtttggccc acccagctgc ggtgttgagt ttgggtgcgg 4980
tctcctgtgc tttgcacctg gcccgcttaa ggcatttgtt acccgtaatg ctcctgtaag 5040
gcatctgcgt ttgtgacatc gttttggtcg ccaggaaggg attggggctc taagcttgag 5100
cggttcatcc ttttcattta tacaggggat gaccagagtc attggcgcta tggaggtgag 5160
acacccaccc gctgcacaga cccaatctgg gaacccagct ctgtggatct cccctacagc 5220
cgtccctgaa cactggtccc gggcgtccca cccgccgccc accgtcccac cccctcacct 5280
tttctacccg ggttccctaa gttcctgacc taggcgtcag acttcctcac tatactctcc 5340
cacccccaggc gacccgccct ggccccgggt gtccccagcc tgcgcgggcc gcttccagtc 5400
cccggtggat atccgccccc agctcgccgc cttctgcccg gccctgcgcc ccctggaact 5460
cctgggcttc cagctcccgc cgctcccaga actgcgcctg cgcaacaatg gccacagtgg 5520
tgaggggggtc tccccgccga gacttgggga tggggcgggg cgcagggaag ggaaccgtcg 5580
cgcagtgcct gcccgggggt tgggctggcc ctaccgggcg gggccggctc acttgcctct 5640
ccctacgcag tgcaactgac cctgcctcct gggctagaga tggctctggg tcccgggcgg 5700
gagtaccggg ctctgcagct gcatctgcac tgggggggctg caggtcgtcc gggctcggag 5760
cacactgtgg aaggccaccg tttccctgcc gaggtgagcg cggactggcc gagaaggggc 5820
aaaggagcgg ggcggacggg ggccagagac gtggccctct cctaccctcg tgtccttttc 5880
agatccacgt ggttcacctc agcaccgcct ttgccagagt tgacgaggcc ttggggcgcc 5940
cgggaggcct ggccgtgttg gccgcctttc tggaggtacc agatcctgga cacccccctac 6000
tccccgcttt cccatcccat gctcctcccg gactctatcg tggagccaga gaccccatcc 6060
cagcaagctc actcaggccc ctggctgaca aactcattca cgcactgttt gttcatttaa 6120
cacccactgt gaaccaggca ccagccccca acaaggattc tgaagctgta ggtccttgcc 6180
tctaaggagc ccacagccag tgggggaggc tgacatgaca gacacatagg aaggacatag 6240
taaagatggt ggtcacagag gaggtgacac ttaaagcctt cactggtaga aaagaaaagg 6300
aggtgttcat tgcagaggaa acagaatgtg caaagactca gaatatggcc tatttaggga 6360
atggctacat acaccatgat tagaggaggc ccagtaaagg gaagggatgg tgagatgcct 6420
gctaggttca ctcactcact tttatttatt tatttatttt tttgacagtc tctctgtcgc 6480
ccaggctgga gtgcagtggt gtgatcttgg gtcactgcaa cttccgcctc ccgggttcaa 6540
gggattctcc tgcctcagct tcctgagtag ctggggttac aggtgtgtgc caccatgccc 6600
agctaatttt tttttgtatt tttagtagac agggtttcac catgttggtc aggctggtct 6660

caaactcctg gcctcaagtg atccgcctga ctcagcctac caaagtgctg attacaagtg 6720
tgagccaccg tgcccagcca cactcactga ttctttaatg ccagccacac agcacaaagt 6780
tcagagaaat gcctccatca tagcatgtca atatgttcat actcttaggt tcatgatgtt 6840
cttaacatta ggttcataag caaaataaga aaaaagaata ataaataaaa gaagtggcat 6900
gtcaggacct cacctgaaaa gccaaacaca gaatcatgaa ggtgaatgca gaggtgacac 6960
caacacaaag gtgtatatat ggtttcctgt ggggagtatg tacggaggca gcagtgagtg 7020
agactgcaaa cgtcagaagg gcacgggtca ctgagagcct agtatcctag taaagtgggc 7080
tctctccctc tctctccagc ttgtcattga aaaccagtcc accaagcttg ttggttcgca 7140
cagcaagagt acatagagtt tgaaataata cataggattt taagagggag acactgtctc 7200
taaaaaaaaa aacaacagca acaacaaaaa gcaacaacca ttacaatttt atgttccctc 7260
agcattctca gagctgagga atgggagagg actatgggaa ccccccttcat gttccggcct 7320
tcagccatgg ccctggatac atgcactcat ctgtcttaca atgtcattcc cccaggaggg 7380
cccggaagaa aacagtgcct atgagcagtt gctgtctcgc ttggaagaaa tcgctgagga 7440
aggtcagttt gttggtctgg ccactaatct ctgtggccta gttcataaag aatcaccctt 7500
tggagcttca ggtctgaggc tggagatggg ctccctccag tgcaggaggg attgaagcat 7560
gagccagcgc tcatcttgat aataaccatg aagctgacag acacagttac ccgcaaacgg 7620
ctgcctacag attgaaaacc aagcaaaaac cgccgggcac ggtggctcac gcctgtaatc 7680
ccagcacttt gggaggccaa ggcaggtgga tcacgaggtc aagagatcaa gaccatcctg 7740
gccaacatgg tgaaacccca tctctactaa aaatacgaaa aaatagccag gcgtggtggc 7800
gggtgcctgt aatcccagct actcgggagg ctgaggcagg agaatggcat gaacccggga 7860
ggcagaagtt gcagtgagcc gagatcgtgc cactgcactc cagcctgggc aacagagcga 7920
gactcttgtc tcaaaaaaaa aaaaaaaaaa gaaaaccaag caaaaaccaa aatgagacaa 7980
aaaaaacaag accaaaaaat ggtgtttgga aattgtcaag gtcaagtctg gagagctaaa 8040
ctttttctga gaactgttta tctttaataa gcatcaaata ttttaacttt gtaaatactt 8100
ttgttggaaa tcgttctctt cttagtcact cttgggtcat tttaaatctc acttactcta 8160
ctagaccttt taggtttctg ctagactagg tagaactctg cctttgcatt tcttgtgtct 8220
gttttgtata gttatcaata ttcatattta tttacaagtt attcagatca ttttttcttt 8280
tctttttttt ttttttttt ttttttacat ctttagtaga gacagggttt caccatattg 8340
gccaggctgc tctcaaactc ctgaccttgt gatccaccag cctcggcctc ccaaagtgct 8400
gggattcatt ttttcttttt aatttgctct gggcttaaac ttgtggccca gcactttatg 8460
atggtacaca gagttaagag tgtagactca gacggtcttt cttctttcct tctcttcctt 8520
cctcccttcc ctcccacctt cccttctctc cttcctttct ttcttcctct cttgcttcct 8580
caggcctctt ccagttgctc caaagccctg tacttttttt tgagttaacg tcttatggga 8640
agggcctgca cttagtgaag aagtggtctc agagttgagt taccttggct tctgggaggt 8700
gaaactgtat ccctataccc tgaagcttta agggggtgca atgtagatga gaccccaaca 8760
tagatcctct tcacaggctc agagactcag gtcccaggac tggacatatc tgcactcctg 8820
ccctctgact tcagccgcta cttccaatat gaggggtctc tgactacacc gccctgtgcc 8880
cagggtgtca tctggactgt gtttaaccag acagtgatgc tgagtgctaa gcaggtgggc 8940
ctggggtgtg tgtggacaca gtgggtgcgg gggaaagagg atgtaagatg agatgagaaa 9000
caggagaaga aagaaatcaa ggctgggctc tgtggcttac gcctataatc ccaccacgtt 9060
gggaggctga ggtgggagaa tggtttgagc ccaggagttc aagacaaggc ggggcaacat 9120
agtgtgaccc catctctacc aaaaaaaccc caacaaaacc aaaaatagcc gggcatggtg 9180
gtatgcggcc tagtcccagc tactcaagga ggctgaggtg ggaagatcgc ttgattccag 9240
gagtttgaga ctgcagtgag ctatgatccc accactgcct accatcttta ggatacattt 9300
atttatttat aaaagaaatc aagaggctgg atggggaata caggagctgg agggtggagc 9360
cctgaggtgc tggttgtgag ctggcctggg acccttgttt cctgtcatgc catgaaccca 9420

cccacactgt ccactgacct ccctagctcc acaccctctc tgacaccctg tggggacctg 9480
gtgactctcg gctacagctg aacttccgag cgacgcagcc tttgaatggg cgagtgattg 9540
aggcctcctt ccctgctgga gtggacagca gtcctcgggc tgctgagcca ggtacagctt 9600
tgtctggttt ccccccagcc agtagtccct tatcctccca tgtgtgtgcc agtgtctgtc 9660
attggtggtc acagcccgcc tctcacatct ccttttttctc tccagtccag ctgaattcct 9720
gcctggctgc tggtgagtct gcccctcctc ttggtcctga tgccaggaga ctcctcagca 9780
ccattcagcc ccagggctgc tcaggaccgc ctctgctccc tctccttttc tgcagaacag 9840
accccaaccc caatattaga gaggcagatc atggtgggga ttcccccatt gtccccagag 9900
gctaattgat tagaatgaag cttgagaaat ctcccagcat ccctctcgca aaagaatccc 9960
ccccccttt tttaaagata gggtctcact ctgtttgccc caggctgggg tgttgtggca 10020
cgatcatagc tcactgcagc ctcgaactcc taggctcagg caatcctttc accttagctt 10080
ctcaaagcac tgggactgta ggcatgagcc actgtgcctg gccccaaacg gccctttac 10140
ttggctttta ggaagcaaaa acggtgctta tcttaccccct tctcgtgtat ccaccctcat 10200
cccttggctg gcctcttctg gagactgagg cactatgggg ctgcctgaga actcggggca 10260
ggggtggtgg agtgcactga ggcaggtgtt gaggaactct gcagacccct cttccttccc 10320
aaagcagccc tctctgctct ccatcgcagg tgacatccta gccctggttt ttggcctcct 10380
ttttgctgtc accagcgtcg cgttccttgt gcagatgaga aggcagcaca ggtattacac 10440
tgacctttc ttcaggcaca agcttccccc acccttgtgg agtcacttca tgcaaagcgc 10500
atgcaaatga gctgctcctg ggccagtttt ctgattagcc tttcctgttg tgtacacaca 10560
gaaggggaac caaaggggt gtgagctacc gcccagcaga ggtagccgag actggagcct 10620
agaggctgga tcttggagaa tgtgagaagc cagccagagg catctgaggg ggagccggta 10680
actgtcctgt cctgctcatt atgccacttc cttttaactg ccaagaaatt ttttaaaata 10740
aatatttata ataaaatatg tgttagtcac ctttgttccc caaatcagaa ggaggtattt 10800
gaatttccta ttactgttat tagcaccaat ttagtggtaa tgcatttatt ctattacagt 10860
tcggcctcct tccacacatc actccaatgt gttgctcc 10898

<210> 6
<211> 37
<212> PRT
<213> HUMAN

<400> 6
Met Ala Pro Leu Cys Pro Ser Pro Trp Leu Pro Leu Leu Ile Pro Ala
1 5 10 15

Pro Ala Pro Gly Leu Thr Val Gln Leu Leu Leu Ser Leu Leu Leu Leu
20 25 30

Met Pro Val His Pro
35

<210> 7
<211> 25
<212> DNA

<213> HUMAN

<400> 7
tggggttctt gaggatctcc aggag 25

<210> 8
<211> 26
<212> DNA
<213> HUMAN

<400> 8
ctctaacttc agggagccct cttctt 26

<210> 9
<211> 48
<212> DNA
<213> HUMAN

<220>
<221> primer_bind
<222> (1)..(48)
<223> anchor primer that anneals to the homopolymeric tail.

<220>
<221> inosine
<222> (36)..(37) (41)..(42) (46)..(47)
<223> each of the modified_bases at positions (36), (37), (41), (42), (46) and (47) are inosine

<400> 9
cuacuacuac uaggccacgc gtcgactagt acgggaaggg aagggaag 48

<210> 10
<211> 6
<212> PRT
<213> HUMAN

<400> 10
Glu Glu Asp Leu Pro Ser
1 5

<210> 11

<211> 6
<212> PRT
<213> HUMAN

<400> 11
Gly Glu Asp Asp Pro Leu
1 5

<210> 12
<211> 21
<212> PRT
<213> HUMAN

<400> 12
Asn Asn Ala His Arg Asp Lys Glu Gly Asp Asp Gln Ser His Trp Arg
1 5 10 15

Tyr Gly Gly Asp Pro
20

<210> 13
<211> 16
<212> PRT
<213> HUMAN

<400> 13
His Pro Gln Arg Leu Pro Arg Met Gln Glu Asp Ser Pro Leu Gly Gly
1 5 10 15

<210> 14
<211> 24
<212> PRT
<213> HUMAN

<400> 14
Glu Glu Asp Ser Pro Arg Glu Glu Asp Pro Pro Gly Glu Glu Asp Leu
1 5 10 15

Pro Gly Glu Glu Asp Leu Pro Gly
20

<210> 15

<211> 13
<212> PRT
<213> HUMAN

<400> 15
Leu Glu Glu Gly Pro Glu Glu Asn Ser Ala Tyr Glu Gln
1 5 10

<210> 16
<211> 16
<212> PRT
<213> HUMAN

<400> 16
Met Arg Arg Gln His Arg Arg Gly Thr Lys Gly Gly Val Ser Tyr Arg
1 5 10 15

<210> 17
<211> 45
<212> DNA
<213> HUMAN

<400> 17
gtcgctagct ccatgggtca tatgcagagg ttgccccgga tgcag 45

<210> 18
<211> 43
<212> DNA
<213> HUMAN

<400> 18
gaagatctct tactcgagca ttctccaaga tccagcctct agg 43

<210> 19
<211> 10
<212> DNA
<213> HUMAN

<400> 19
ctccatctct 10

<210> 20
<211> 10
<212> DNA
<213> HUMAN

<400> 20
ccacccccat 10

<210> 21

<400> 21
000

<210> 22
<211> 8
<212> PRT
<213> HUMAN

<400> 22
Leu Glu His His His His His His
1 5

<210> 23
<211> 10
<212> DNA
<213> HUMAN

<220>
<221> misc_feature
<222> (1)..(10)

<400> 23
yyycayyyyy 10

<210> 24
<211> 10
<212> DNA
<213> HUMAN

<300>
<301> Locker and Buzard,
<303> DNA Sequencing and Mapping
<304> 1

<306> 3-11
<307> 1990

<400> 24
tgtgagactt 10

<210> 25
<211> 4
<212> PRT
<213> HUMAN

<220>
<221> SITE
<222> (1)..(4)
<223> sequence element defined by Suzuki, J. Mol. Biol., 207: 61-84 (1989) as motif frequently found in gene regulatory proteins.

<220>
<221> VARIANTS
<222> (3)..(4)
<223> variants in sequence element defined by Suzuki, J. Mol. Biol., 207: 61-84 (1989) as motif frequently found in gene regulatory proteins.

<400> 25
Ser Pro Xaa Xaa
1

<210> 26
<211> 4
<212> PRT
<213> HUMAN

<220>
<221> SITE
<222> (1)..(4)
<223> sequence element defined by Suzuki, J. Mol. Biol., 207: 61-84 (1989) as a motif frequently found in gene regulatory proteins.

<220>
<221> VARIANTS
<222> (3)..(4)
<223> variants in sequence element defined by Suzuki, J. Mol. Biol., 207: 61-84 (1989) as a motif frequently found in gene regulatory proteins.

<400> 26
Thr Pro Xaa Xaa
1

<210> 27
<211> 540
<212> DNA
<213> HUMAN

<220>
<221> promoter
<222> (1)..(540)

<400> 27
cttgcttttc attcaagctc aagtttgtct cccacatacc cattacttaa ctcaccctcg 60
ggctccccta gcagcctgcc ctacctcttt acctgcttcc tggtggagtc agggatgtat 120
acatgagctg ctttccctct cagccagagg acatgggggg ccccagctcc cctgcctttc 180
cccttctgtg cctggagctg ggaagcaggc cagggttagc tgaggctggc tggcaagcag 240
ctgggtggtg ccagggagag cctgcatagt gccaggtggt gccttgggtt ccaagctagt 300
ccatggcccc gataaccttc tgcctgtgca cacacctgcc cctcactcca cccccatcct 360
agctttggta tgggggagag ggcacagggc cagacaaacc tgtgagactt tggctccatc 420
tctgcaaaag ggcgctctgt gagtcagcct gctcccctcc aggcttgctc ctcccccacc 480
cagctctcgt ttccaatgca cgtacagccc gtacacaccg tgtgctggga caccccacag 540

<210> 28
<211> 445
<212> DNA
<213> HUMAN

<220>
<221> exon
<222> (1)
<223> 1st MN exon

<400> 28
gcccgtacac accgtgtgct gggacacccc acagtcagcc gcatggctcc cctgtgcccc 60
agcccctggc tccctctgtt gatcccggcc cctgctccag gcctcactgt gcaactgctg 120
ctgtcactgc tgcttctggt gcctgtccat ccccagaggt tgccccggat gcaggaggat 180
tccccccttgg gaggaggctc ttctggggaa gatgacccac tgggcgagga ggatctgccc 240
agtgaagagg attcacccag agaggaggat ccacccggag aggaggatct acctggagag 300
gaggatctac ctggagagga ggatctacct gaagttaagc ctaaatcaga agaagagggc 360
tccctgaagt tagaggatct acctactgtt gaggctcctg gagatcctca agaaccccag 420
aataatgccc acagggacaa agaag 445

<210> 29
<211> 30
<212> DNA
<213> HUMAN

<220>
<221> exon
<222> (1)
<223> 2nd MN exon

<400> 29
gggatgacca gagtcattgg cgctatggag 30

<210> 30
<211> 171
<212> DNA
<213> HUMAN

<220>
<221> exon
<222> (1)
<223> 3rd MN exon

<400> 30
gcgacccgcc ctggccccgg gtgtccccag cctgcgcggg ccgcttccag tccccggtgg 60
atatccgccc ccagctcgcc gccttctgcc cggccctgcg ccccctggaa ctcctgggct 120
tccagctccc gccgctccca gaactgcgcc tgcgcaacaa tggccacagt g 171

<210> 31
<211> 143
<212> DNA
<213> HUMAN

<220>
<221> exon
<222> (1)
<223> 4th MN exon

<400> 31
tgcaactgac cctgcctcct gggctagaga tggctctggg tcccgggcgg gagtaccggg 60
ctctgcagct gcatctgcac tgggggggctg caggtcgtcc gggctcggag cacactgtgg 120
aaggccaccg tttccctgcc gag 143

<210> 32
<211> 93
<212> DNA
<213> HUMAN

<220>
<221> exon
<222> (1)
<223> 5th MN exon

<400> 32
atccacgtgg ttcacctcag caccgccttt gccagagttg acgaggcctt ggggcgcccg 60
ggaggcctgg ccgtgttggc cgcctttctg gag 93

<210> 33
<211> 67
<212> DNA
<213> HUMAN

<220>
<221> exon
<222> (1)
<223> 6th MN exon

<400> 33
gagggcccgg aagaaaacag tgcctatgag cagttgctgt ctcgcttgga agaaatcgct 60
gaggaag 67

<210> 34
<211> 158
<212> DNA
<213> HUMAN

<220>
<221> exon
<222> (1)
<223> 7th MN exon

<400> 34
gctcagagac tcaggtccca ggactggaca tatctgcact cctgccctct gacttcagcc 60
gctacttcca atatgagggg tctctgacta caccgccctg tgcccagggt gtcatctgga 120
ctgtgtttaa ccagacagtg atgctgagtg ctaagcag 158

<210> 35
<211> 145
<212> DNA
<213> HUMAN

<220>
<221> exon
<222> (1)
<223> 8th MN exon

<400> 35
ctccacaccc tctctgacac cctgtgggga cctggtgact ctcggctaca gctgaacttc 60
cgagcgacgc agcctttgaa tgggcgagtg attgaggcct ccttccctgc tggagtggac 120
agcagtcctc gggctgctga gccag 145

<210> 36
<211> 27
<212> DNA
<213> HUMAN

<220>
<221> exon
<222> (1)
<223> 9th MN exon

<400> 36
tccagctgaa ttcctgcctg gctgctg 27

<210> 37
<211> 82
<212> DNA
<213> HUMAN

<220>
<221> exon
<222> (1)
<223> 10th MN exon

<400> 37
gtgacatcct agccctggtt tttggcctcc tttttgctgt caccagcgtc gcgttccttg 60
tgcagatgag aaggcagcac ag 82

<210> 38

<211> 191
<212> DNA
<213> HUMAN

<220>
<221> exon
<222> (1)
<223> 11th MN exon

<400> 38
aaggggaacc aaaggggtg tgagctaccg cccagcagag gtagccgaga ctggagccta 60
gaggctggat cttggagaat gtgagaagcc agccagaggc atctgagggg gagccggtaa 120
ctgtcctgtc ctgctcatta tgccacttcc ttttaactgc caagaaattt tttaaaataa 180
atatttataa t 191

<210> 39
<211> 1174
<212> DNA
<213> HUMAN

<220>
<221> intron
<222> (1)..(1174)
<223> 1st MN intron

<400> 39
gtaagtggtc atcaatctcc aaatccaggt tccaggaggt tcatgactcc cctcccatac 60
cccagcctag gctctgttca ctcagggaag gaggggagac tgtactcccc acagaagccc 120
ttccagaggt cccataccaa tatccccatc cccactctcg gaggtagaaa gggacagatg 180
tggagagaaa ataaaaaggg tgcaaaagga gagaggtgag ctggatgaga tgggagagaa 240
gggggaggct ggagaagaga aagggatgag aactgcagat gagagaaaaa atgtgcagac 300
agaggaaaaa aataggtgga gaaggagagt cagagagttt gaggggaaga gaaaaggaaa 360
gcttgggagg tgaagtgggt accagagaca agcaagaaga gctggtagaa gtcatctcat 420
cttaggctac aatgaggaat tgagacctag gaagaaggga cacagcaggt agagaaacgt 480
ggcttcttga ctcccaagcc aggaatttgg ggaaaggggt tggagaccat acaaggcaga 540
gggatgagtg gggagaagaa agaagggaga aaggaaagat ggtgtactca ctcatttggg 600
actcaggact gaagtgccca ctcacttttt ttttttttt ttttgagaca aactttcact 660
tttgttgccc aggctggagt gcaatggcgc gatctcggct cactgcaacc tccacctccc 720
gggttcaagt gattctcctg cctcagcctc tagccaagta gctgcgatta caggcatgcg 780
ccaccacgcc cggctaattt ttgtattttt agtagagacg gggtttcgcc atgttggtca 840
ggctggtctc gaactcctga tctcaggtga tccaaccacc ctggcctccc aaagtgctgg 900
gattataggc gtgagccaca gcgcctggcc tgaagcagcc actcactttt acagacccta 960
agacaatgat tgcaagctgg taggattgct gtttggccca cccagctgcg gtgttgagtt 1020
tgggtgcggt ctcctgtgct ttgcacctgg cccgcttaag gcatttgtta cccgtaatgc 1080
tcctgtaagg catctgcgtt tgtgacatcg ttttggtcgc caggaaggga ttggggctct 1140

aagcttgagc ggttcatcct tttcatttat acag 1174

<210> 40
<211> 193
<212> DNA
<213> HUMAN

<220>
<221> intron
<222> (1)..(193)
<223> 2nd MN intron

<400> 40
gtgagacacc cacccgctgc acagacccaa tctgggaacc cagctctgtg gatctcccct 60
acagccgtcc ctgaacactg gtcccgggcg tcccacccgc cgcccaccgt cccacccccc 120
cacctttttct acccgggttc cctaagttcc tgacctaggc gtcagacttc ctcactatac 180
tctcccaccc cag 193

<210> 41
<211> 131
<212> DNA
<213> HUMAN

<220>
<221> intron
<222> (1)..(131)
<223> 3rd MN intron

<400> 41
gtgaggggtt ctccccgccg agacttgggg atggggcggg gcgcagggaa gggaaccgtc 60
gcgcagtgcc tgcccggggg ttgggctggc cctaccgggc ggggccggct cacttgcctc 120
tccctacgca g 131

<210> 42
<211> 89
<212> DNA
<213> HUMAN

<220>
<221> intron
<222> (1)..(89)
<223> 4th MN intron

<400> 42
gtgagcgcgg actggccgag aaggggcaaa ggagcggggc ggacgggggc cagagacgtg 60
gccctctcct accctcgtgt ccttttcag 89

<210> 43
<211> 1400
<212> DNA
<213> HUMAN

<220>
<221> intron
<222> (1)..(1400)
<223> 5th MN intron

<400> 43
gtaccagatc ctggacaccc cctactcccc gctttcccat cccatgctcc tcccggactc 60
tatcgtggag ccagagaccc catcccagca agctcactca ggcccctggc tgacaaactc 120
attcacgcac tgtttgttca tttaacaccc actgtgaacc aggcaccagc ccccaacaag 180
gattctgaag ctgtaggtcc ttgcctctaa ggagcccaca gccagtgggg gaggctgaca 240
tgacagacac ataggaagga catagtaaag atggtggtca cagaggaggt gacacttaaa 300
gccttcactg gtagaaaaga aaaggaggtg ttcattgcag aggaaacaga atgtgcaaag 360
actcagaata tggcctattt agggaatggc tacatacacc atgattagag gaggcccagt 420
aaagggaagg gatggtgaga tgcctgctag gttcactcac tcacttttat ttatttattt 480
atttttttga cagtctctct gtcgcccagg ctggagtgca gtggtgtgat cttgggtcac 540
tgcaacttcc gcctcccggg ttcaagggat tctcctgcct cagcttcctg agtagctggg 600
gttacaggtg tgtgccacca tgcccagcta attttttttt gtatttttag tagacagggt 660
ttcaccatgt tggtcaggct ggtctcaaac tcctggcctc aagtgatccg cctgactcag 720
cctaccaaag tgctgattac aagtgtgagc caccgtgccc agccacactc actgattctt 780
taatgccagc cacacagcac aaagttcaga gaaatgcctc catcatagca tgtcaatatg 840
ttcatactct taggttcatg atgttcttaa cattaggttc ataagcaaaa taagaaaaaa 900
gaataataaa taaaagaagt ggcatgtcag gacctcacct gaaaagccaa acacagaatc 960
atgaaggtga atgcagaggt gacaccaaca caaaggtgta tatatggttt cctgtgggga 1020
gtatgtacgg aggcagcagt gagtgagact gcaaacgtca gaagggcacg ggtcactgag 1080
agcctagtat cctagtaaag tgggctctct ccctctctct ccagcttgtc attgaaaacc 1140
agtccaccaa gcttgttggt tcgcacagca agagtacata gagtttgaaa taatacatag 1200
gattttaaga gggagacact gtctctaaaa aaaaaaacaa cagcaacaac aaaaagcaac 1260
aaccattaca attttatgtt ccctcagcat tctcagagct gaggaatggg agaggactat 1320
gggaaccccc ttcatgttcc ggccttcagc catggccctg gatacatgca ctcatctgtc 1380
ttacaatgtc attcccccag 1400

<210> 44
<211> 1334
<212> DNA
<213> HUMAN

<220>
<221> intron
<222> (1)..(1334)
<223> 6th MN intron

<400> 44
gtcagtttgt tggtctggcc actaatctct gtggcctagt tcataaagaa tcacccttg 60
gagcttcagg tctgaggctg gagatgggct ccctccagtg caggagggat tgaagcatga 120
gccagcgctc atcttgataa taaccatgaa gctgacagac acagttaccc gcaaacggct 180
gcctacagat tgaaaaccaa gcaaaaaccg ccgggcacgg tggctcacgc ctgtaatccc 240
agcactttgg gaggccaagg caggtggatc acgaggtcaa gagatcaaga ccatcctggc 300
caacatggtg aaaccccatc tctactaaaa atacgaaaaa atagccaggc gtggtggcgg 360
gtgcctgtaa tcccagctac tcgggaggct gaggcaggag aatggcatga acccgggagg 420
cagaagttgc agtgagccga gatcgtgcca ctgcactcca gcctgggcaa cagagcgaga 480
ctcttgtctc aaaaaaaaaa aaaaaaaaga aaaccaagca aaaaccaaaa tgagacaaaa 540
aaaacaagac caaaaaatgg tgtttggaaa ttgtcaaggt caagtctgga gagctaaact 600
ttttctgaga actgtttatc tttaataagc atcaaatatt ttaactttgt aaatactttt 660
gttggaaatc gttctcttct tagtcactct tgggtcattt taaatctcac ttactctact 720
agaccttta ggtttctgct agactaggta gaactctgcc tttgcatttc ttgtgtctgt 780
tttgtatagt tatcaatatt catatttatt tacaagttat tcagatcatt ttttcttttc 840
ttttttttt ttttttttt ttttacatct ttagtagaga cagggtttca ccatattggc 900
caggctgctc tcaaactcct gaccttgtga tccaccagcc tcggcctccc aaagtgctgg 960
gattcatttt ttctttttaa tttgctctgg gcttaaactt gtggcccagc actttatgat 1020
ggtacacaga gttaagagtg tagactcaga cggtctttct tctttccttc tcttccttcc 1080
tcccttccct cccaccttcc cttctctcct tcctttcttt cttcctctct tgcttcctca 1140
ggcctcttcc agttgctcca aagccctgta ctttttttg agttaacgtc ttatgggaag 1200
ggcctgcact tagtgaagaa gtggtctcag agttgagtta ccttggcttc tgggaggtga 1260
aactgtatcc ctataccctg aagctttaag ggggtgcaat gtagatgaga ccccaacata 1320
gatcctcttc acag 1334

<210> 45
<211> 512
<212> DNA
<213> HUMAN

<220>
<221> intron
<222> (1)..(512)
<223> 7th MN intron

<400> 45
gtgggcctgg ggtgtgtgtg gacacagtgg gtgcggggga aagaggatgt aagatgagat 60
gagaaacagg agaagaaaga aatcaaggct gggctctgtg gcttacgcct ataatcccac 120
cacgttggga ggctgaggtg ggagaatggt ttgagcccag gagttcaaga caaggcgggg 180
caacatagtg tgaccccatc tctaccaaaa aaaccccaac aaaaccaaaa atagccgggc 240

atggtggtat gcggcctagt cccagctact caaggaggct gaggtgggaa gatcgcttga 300
ttccaggagt ttgagactgc agtgagctat gatcccacca ctgcctacca tctttaggat 360
acatttattt atttataaaa gaaatcaaga ggctggatgg ggaatacagg agctggaggg 420
tggagccctg aggtgctggt tgtgagctgg cctgggaccc ttgtttcctg tcatgccatg 480
aacccaccca cactgtccac tgacctccct ag 512

<210> 46
<211> 114
<212> DNA
<213> HUMAN

<220>
<221> intron
<222> (1)..(114)
<223> 8th MN intron

<400> 46
gtacagcttt gtctggtttc cccccagcca gtagtccctt atcctcccat gtgtgtgcca 60
gtgtctgtca ttggtggtca cagcccgcct ctcacatctc ctttttctct ccag 114

<210> 47
<211> 617
<212> DNA
<213> HUMAN

<220>
<221> intron
<222> (1)..(617)
<223> 9th MN intron

<400> 47
gtgagtctgc ccctcctctt ggtcctgatg ccaggagact cctcagcacc attcagcccc 60
agggctgctc aggaccgcct ctgctccctc tccttttctg cagaacagac cccaacccca 120
atattagaga ggcagatcat ggtggggatt cccccattgt ccccagaggc taattgatta 180
gaatgaagct tgagaaatct cccagcatcc ctctcgcaaa agaatccccc ccccttttt 240
taaagatagg gtctcactct gtttgcccca ggctggggtg ttgtggcacg atcatagctc 300
actgcagcct cgaactccta ggctcaggca atcctttcac cttagcttct caaagcactg 360
ggactgtagg catgagccac tgtgcctggc cccaaacggc ccttttactt ggcttttagg 420
aagcaaaaac ggtgcttatc ttacccctc tcgtgtatcc accctcatcc cttggctggc 480
ctcttctgga gactgaggca ctatggggct gcctgagaac tcggggcagg ggtggtggag 540
tgcactgagg caggtgttga ggaactctgc agacccctct tccttcccaa agcagccctc 600
tctgctctcc atcgcag 617

<210> 48
<211> 130
<212> DNA
<213> HUMAN

<220>
<221> intron
<222> (1)..(130)
<223> 10th MN intron

<400> 48
gtattacact gacccttttct tcaggcacaa gcttccccca cccttgtgga gtcacttcat 60
gcaaagcgca tgcaaatgag ctgctcctgg gccagttttc tgattagcct ttcctgttgt 120
gtacacacag 130

<210> 49
<211> 1401
<212> DNA
<213> HUMAN

<400> 49
caaactttca cttttgttgc ccaggctgga gtgcaatggc gcgatctcgg ctcactgcaa 60
cctccacctc ccgggttcaa gtgattctcc tgcctcagcc tctagccaag tagctgcgat 120
tacaggcatg cgccaccacg cccggctaat ttttgtattt ttagtagaga cggggtttcg 180
ccatgttggt caggctggtc tcgaactcct gatctcaggt gatccaacca ccctggcctc 240
ccaaagtgct gggattatag gcgtgagcca cagcgcctgg cctgaagcag ccactcactt 300
ttacagaccc taagacaatg attgcaagct ggtaggattg ctgtttggcc cacccagctg 360
cggtgttgag tttgggtgcg gtctcctgtg ctttgcacct ggcccgctta aggcatttgt 420
tacccgtaat gctcctgtaa ggcatctgcg tttgtgacat cgttttggtc gccaggaagg 480
gattggggct ctaagcttga gcggttcatc cttttcattt atacagggga tgaccagagt 540
cattggcgct atggaggtga gacacccacc cgctgcacag acccaatctg ggaacccagc 600
tctgtggatc tcccctacag ccgtccctga acactggtcc cgggcgtccc acccgccgcc 660
caccgtccca ccccctcacc ttttctaccc gggttcccta agttcctgac ctaggcgtca 720
gacttcctca ctatactctc ccaccccagg cgacccgccc tggccccggg tgtccccagc 780
ctgcgcgggc cgcttccagt ccccggtgga tatccgcccc cagctcgccg ccttctgccc 840
ggccctgcgc cccctggaac tcctgggctt ccagctcccg ccgctcccag aactgcgcct 900
gcgcaacaat ggccacagtg gtgagggggt ctccccgccg agacttgggg atggggcggg 960
gcgcagggaa gggaaccgtc gcgcagtgcc tgcccggggg ttgggctggc cctaccgggc 1020
ggggccggct cacttgcctc tccctacgca gtgcaactga ccctgcctcc tgggctagag 1080
atggctctgg gtcccgggcg ggagtaccgg gctctgcagc tgcatctgca ctgggggggct 1140
gcaggtcgtc cgggctcgga gcacactgtg gaaggccacc gtttccctgc cgaggtgagc 1200
gcggactggc cgagaagggg caaaggagcg gggcggacgg gggccagaga cgtggccctc 1260
tcctaccctc gtgtcctttt cagatccacg tggttcacct cagcaccgcc tttgccagag 1320
ttgacgaggc cttggggcgc ccgggaggcc tggccgtgtt ggccgccttt ctggaggtac 1380
cagatcctgg acacccccta c 1401

<210> 50
<211> 59
<212> PRT
<213> HUMAN

<400> 50
Ser Ser Gly Glu Asp Asp Pro Leu Gly Glu Glu Asp Leu Pro Ser Glu
1 5 10 15

Glu Asp Ser Pro Arg Glu Glu Asp Pro Pro Gly Glu Glu Asp Leu Pro
20 25 30

Gly Glu Glu Asp Leu Pro Gly Glu Glu Asp Leu Pro Glu Val Lys Pro
35 40 45

Lys Ser Glu Glu Glu Gly Ser Leu Lys Leu Glu
50 55

<210> 51
<211> 257
<212> PRT
<213> HUMAN

<400> 51
Gly Asp Asp Gln Ser His Trp Arg Tyr Gly Gly Asp Pro Pro Trp Pro
1 5 10 15

Arg Val Ser Pro Ala Cys Ala Gly Arg Phe Gln Ser Pro Val Asp Ile
20 25 30

Arg Pro Gln Leu Ala Ala Phe Cys Pro Ala Leu Arg Pro Leu Glu Leu
35 40 45

Leu Gly Phe Gln Leu Pro Pro Leu Pro Glu Leu Arg Leu Arg Asn Asn
50 55 60

Gly His Ser Val Gln Leu Thr Leu Pro Pro Gly Leu Glu Met Ala Leu
65 70 75 80

Gly Pro Gly Arg Glu Tyr Arg Ala Leu Gln Leu His Leu His Trp Gly
85 90 95

Ala Ala Gly Arg Pro Gly Ser Glu His Thr Val Glu Gly His Arg Phe
100 105 110

```
Pro Ala Glu Ile His Val Val His Leu Ser Thr Ala Phe Ala Arg Val
        115                 120                 125

Asp Glu Ala Leu Gly Arg Pro Gly Gly Leu Ala Val Leu Ala Ala Phe
    130                 135                 140

Leu Glu Glu Gly Pro Glu Glu Asn Ser Ala Tyr Glu Gln Leu Leu Ser
145                 150                 155                 160

Arg Leu Glu Glu Ile Ala Glu Glu Gly Ser Glu Thr Gln Val Pro Gly
                165                 170                 175

Leu Asp Ile Ser Ala Leu Leu Pro Ser Asp Phe Ser Arg Tyr Phe Gln
            180                 185                 190

Tyr Glu Gly Ser Leu Thr Thr Pro Pro Cys Ala Gln Gly Val Ile Trp
        195                 200                 205

Thr Val Phe Asn Gln Thr Val Met Leu Ser Ala Lys Gln Leu His Thr
    210                 215                 220

Leu Ser Asp Thr Leu Trp Gly Pro Gly Asp Ser Arg Leu Gln Leu Asn
225                 230                 235                 240

Phe Arg Ala Thr Gln Pro Leu Asn Gly Arg Val Ile Glu Ala Ser Phe
                245                 250                 255

Pro
```

<210> 52
<211> 20
<212> PRT
<213> HUMAN

<400> 52
```
Ile Leu Ala Leu Val Phe Gly Leu Leu Phe Ala Val Thr Ser Val Ala
  1               5                  10                  15

Phe Leu Val Gln
            20
```

<210> 53
<211> 25

<212> PRT
<213> HUMAN

<400> 53
Met Arg Arg Gln His Arg Arg Gly Thr Lys Gly Gly Val Ser Tyr Arg
1 5 10 15

Pro Ala Glu Val Ala Glu Thr Gly Ala
20 25

<210> 54
<211> 59
<212> PRT
<213> HUMAN

<400> 54
Ser Ala Ser Glu Glu Pro Ser Pro Ser Glu Val Pro Phe Pro Ser Glu
1 5 10 15

Glu Pro Ser Pro Ser Glu Glu Pro Phe Pro Ser Val Arg Pro Phe Pro
20 25 30

Ser Val Val Leu Phe Pro Ser Glu Glu Pro Phe Pro Ser Lys Glu Pro
35 40 45

Ser Pro Ser Glu Glu Pro Ser Ala Ser Glu Glu
50 55

<210> 55
<211> 470
<212> RNA
<213> HUMAN

<400> 55
cauggccccg auaaccuucu gccugugcac acaccugccc cucacuccac ccccauccua 60
gcuuugguau gggggagagg gcacagggcc agacaaaccu gugagacuuu ggcuccaucu 120
cugcaaaagg gcgcucugug agucagccug cuccccucca ggcuugcucc ucccccaccc 180
agcucucguu uccaaugcac guacagcccg uacacaccgu gugcugggac accccacagu 240
cagccgcaug gcucccccugu gccccagccc cuggcucccu cuguugaucc cggccccugc 300
uccaggccuc acugugcaac ugcugcuguc acugcugcuu cuggugccug uccaucccca 360
gagguugccc cggaugcagg aggauucccc cuugggagga ggcucuucug gggaagauga 420
cccacugggc gaggaggauc ugcccaguga agaggauuca cccagagagg 470

<210> 56
<211> 292
<212> DNA
<213> HUMAN

<400> 56
gttttttga gacggagtct tgcatctgtc atgcccaggc tggagtagca gtggtgccat 60
ctcggctcac tgcaagctcc acctcccgag ttcacgccat tttcctgcct cagcctcccg 120
agtagctggg actacaggcg cccgccacca tgcccggcta atttttttgta tttttggtag 180
agacggggtt tcaccgtgtt agccagaatg gtctcgatct cctgacttcg tgatccaccc 240
gcctcggcct cccaaagttc tgggattaca ggtgtgagcc accgcacctg gc 292

<210> 57
<211> 262
<212> DNA
<213> HUMAN

<400> 57
tttctttttt gagacagggt cttgctctgt cacccaggcc agagtgcaat ggtacagtct 60
cagctcactg cagcctcaac cgcctcggct caaaccatca tcccatttca gcctcctgag 120
tagctgggac tacaggcaca tgccattaca cctggctaat ttttttgtat ttctagtaga 180
gacagggttt ggccatgttg cccgggctgg tctcgaactc ctggactcaa gcaatccacc 240
cacctcagcc tcccaaaatg ag 262

<210> 58
<211> 2501
<212> DNA
<213> HUMAN

<220>
<221> misc_feature
<222> (1)..(2501)
<223> region 5' to transcription initiation site as determined by RNase protection assay (nucleotide 3507 of Figures 2A-2F and of SEQ ID NO: 5), corresponding to region of SEQ ID NO: 5 and Figures 2A-2F from nucleotide (7) to nucleotide (2507), in which region some regulatory elements are probably situated.

<220>
<221> unsure what base is at position 1968
<222> (1968)
<223> unsure of base at position 1968, which is the same unknown base as that at position 1974 of SEQ ID NO. 5, i.e., the full-length MN genomic sequence, and of that unknown at position 1968 of SEQ ID NO: 90, and

unknown at position 647 of SEQ ID NO: 110. That unknown base is in the 5' region flanking the transcription initiation site (3507) as determined by RNase protection assay.

<400> 58
tgttgactcg tgaccttacc cccaaccctg tgctctctga aacatgagct gtgtccactc 60
agggttaaat ggattaaggg cggtgcaaga tgtgctttgt taaacagatg cttgaaggca 120
gcatgctcgt taagagtcat caccaatccc taatctcaag taatcaggga cacaaacact 180
gcggaaggcc gcagggtcct ctgcctagga aaaccagaga cctttgttca cttgtttatc 240
tgaccttccc tccactattg tccatgaccc tgccaaatcc ccctctgtga gaaacaccca 300
agaattatca ataaaaaaat aaatttaaaa aaaaaataca aaaaaaaaaa aaaaaaaaaa 360
aaaagactta cgaatagtta ttgataaatg aatagctatt ggtaaagcca agtaaatgat 420
catattcaaa accagacggc catcatcaca gctcaagtct acctgatttg atctctttat 480
cattgtcatt ctttggattc actagattag tcatcatcct caaaattctc ccccaagttc 540
taattacgtt ccaaacattt aggggttaca tgaagcttga acctactacc ttctttgctt 600
ttgagccatg agttgtagga atgatgagtt tacaccttac atgctgggga ttaatttaaa 660
ctttacctct aagtcagttg ggtagccttt ggcttatttt tgtagctaat tttgtagtta 720
atggatgcac tgtgaatctt gctatgatag ttttcctcca cactttgcca ctaggggtag 780
gtaggtactc agttttcagt aattgcttac ctaagaccct aagccctatt tctcttgtac 840
tggcctttat ctgtaatatg ggcatattta atacaatata atttttggag tttttttgtt 900
tgtttgtttg tttgtttttt tgagacggag tcttgcatct gtcatgccca ggctggagta 960
gcagtggtgc catctcggct cactgcaagc tccacctccc gagttcacgc cattttcctg 1020
cctcagcctc ccgagtagct gggactacag gcgcccgcca ccatgcccgg ctaatttttt 1080
gtatttttgg tagagacggg gtttcaccgt gttagccaga atggtctcga tctcctgact 1140
tcgtgatcca cccgcctcgg cctcccaaag ttctgggatt acaggtgtga gccaccgcac 1200
ctggccaatt ttttgagtct tttaaagtaa aaatatgtct tgtaagctgg taactatggt 1260
acatttcctt ttattaatgt ggtgctgacg gtcatatagg ttcttttgag tttggcatgc 1320
atatgctact ttttgcagtc ctttcattac atttttctct cttcatttga agagcatgtt 1380
atatctttta gcttcacttg gcttaaaagg ttctctcatt agcctaacac agtgtcattg 1440
ttggtaccac ttggatcata agtggaaaaa cagtcaagaa attgcacagt aatacttgtt 1500
tgtaagaggg atgattcagg tgaatctgac actaagaaac tcccctacct gaggtctgag 1560
attcctctga cattgctgta tataggcttt tcctttgaca gcctgtgact gcggactatt 1620
tttcttaagc aagatatgct aaagttttgt gagccttttt ccagagagag gtctcatatc 1680
tgcatcaagt gagaacatat aatgtctgca tgtttccata tttcaggaat gtttgcttgt 1740
gttttatgct tttatataga cagggaaact tgttcctcag tgacccaaaa gaggtgggaa 1800
ttgttattgg atatcatcat tggcccacgc tttctgacct tggaaacaat taagggttca 1860
taatctcaat tctgtcagaa ttggtacaag aaatagctgc tatgtttctt gacattccac 1920
ttggtaggaa ataagaatgt gaaactcttc agttggtgtg tgtccctngt ttttttgcaa 1980
tttccttctt actgtgttaa aaaaaagtat gatcttgctc tgagaggtga ggcattctta 2040
atcatgatct ttaaagatca ataatataat cctttcaagg attatgtctt tattataata 2100
aagataattt gtctttaaca gaatcaataa tataatccct taaaggatta tatctttgct 2160
gggcgcagtg gctcacacct gtaatcccag cactttgggt ggccaaggtg gaaggatcaa 2220
atttgcctac ttctatatta tcttctaaag cagaattcat ctctcttccc tcaatatgat 2280
gatattgaca gggtttgccc tcactcacta gattgtgagc tcctgctcag ggcaggtagc 2340
gttttttgtt tttgtttttg ttttttcttt ttgagacagg gtcttgctct gtcacccagg 2400
ccagagtgca atggtacagt ctcagctcac tgcagcctca accgcctcgg ctcaaaccat 2460

catcccattt cagcctcctg agtagctggg actacaggca c 2501

<210> 59
<211> 292
<212> DNA
<213> HUMAN

<220>
<221> misc_feature
<222> (1)

<400> 59
ttttttgag acggagtctt gcatctgtca tgcccaggct ggagtagcag tggtgccatc 60
tcggctcact gcaagctcca cctcccgagt tcacgccatt ttcctgcctc agcctcccga 120
gtagctggga ctacaggcgc ccgccaccat gcccggctaa ttttttgtat ttttggtaga 180
gacggggttt caccgtgtta gccagaatgg tctcgatctc ctgacttcgt gatccacccg 240
cctcggcctc ccaaagttct gggattacag gtgtgagcca ccgcacctgg cc 292

<210> 60
<211> 262
<212> DNA
<213> HUMAN

<400> 60
ttctttttg agacagggtc ttgctctgtc acccaggcca gagtgcaatg gtacagtctc 60
agctcactgc agcctcaacc gcctcggctc aaaccatcat cccatttcag cctcctgagt 120
agctgggact acaggcacat gccattacac ctggctaatt tttttgtatt tctagtagag 180
acagggtttg gccatgttgc ccgggctggt ctcgaactcc tggactcaag caatccaccc 240
acctcagcct cccaaaatga gg 262

<210> 61
<211> 294
<212> DNA
<213> HUMAN

<400> 61
ttttttttg agacaaactt tcacttttgt tgcccaggct ggagtgcaat ggcgcgatct 60
cggctcactg caacctccac ctcccgggtt caagtgattc tcctgcctca gcctctagcc 120
aagtagctgc gattacaggc atgcgccacc acgcccggct aatttttgta tttttagtag 180
agacggggtt tcgccatgtt ggtcaggctg gtctcgaact cctgatctca ggtgatccaa 240
ccaccctggc ctcccaaagt gctgggatta taggcgtgag ccacagcgcc tggc 294

<210> 62
<211> 276
<212> DNA
<213> HUMAN

<400> 62
tgacagtctc tctgtcgccc aggctggagt gcagtggtgt gatcttgggt cactgcaact 60
tccgcctccc gggttcaagg gattctcctg cctcagcttc ctgagtagct ggggttacag 120
gtgtgtgcca ccatgcccag ctaatttttt tttgtatttt tagtagacag ggtttcacca 180
tgttggtcag gctggtctca aactcctggc ctcaagtgat ccgcctgact cagcctacca 240
aagtgctgat tacaagtgtg agccaccgtg cccagc 276

<210> 63
<211> 289
<212> DNA
<213> HUMAN

<400> 63
cgccgggcac ggtggctcac gcctgtaatc ccagcacttt gggaggccaa ggcaggtgga 60
tcacgaggtc aagagatcaa gaccatcctg gccaacatgg tgaaacccca tctctactaa 120
aaatacgaaa aaatagccag gcgtggtggc gggtgcctgt aatcccagct actcgggagg 180
ctgaggcagg agaatggcat gaacccggga ggcagaagtt gcagtgagcc gagatcgtgc 240
cactgcactc cagcctgggc aacagagcga gactcttgtc tcaaaaaaa 289

<210> 64
<211> 298
<212> DNA
<213> HUMAN

<400> 64
aggctgggct ctgtggctta cgcctataat cccaccacgt tgggaggctg aggtgggaga 60
atggtttgag cccaggagtt caagacaagg cggggcaaca tagtgtgacc ccatctctac 120
caaaaaaacc ccaacaaaac caaaaatagc cgggcatggt ggtatgcggc ctagtcccag 180
ctactcaagg aggctgaggt gggaagatcg cttgattcca ggagtttgag actgcagtga 240
gctatgatcc caccactgcc taccatcttt aggatacatt tatttattta taaaagaa 298

<210> 65
<211> 105
<212> DNA
<213> HUMAN

<400> 65
ttttttacat ctttagtaga gacagggttt caccatattg gccaggctgc tctcaaactc 60

ctgaccttgt gatccaccag cctcggcctc ccaaagtgct gggat 105

<210> 66
<211> 83
<212> DNA
<213> HUMAN

<400> 66
cctcgaactc ctaggctcag gcaatccttt caccttagct tctcaaagca ctgggactgt 60
aggcatgagc cactgtgcct ggc 83

<210> 67
<211> 11
<212> DNA
<213> HUMAN

<400> 67
agaaggtaag t 11

<210> 68
<211> 11
<212> DNA
<213> HUMAN

<400> 68
tggaggtgag a 11

<210> 69
<211> 11
<212> DNA
<213> HUMAN

<400> 69
cagtcgtgag g 11

<210> 70
<211> 11
<212> DNA
<213> HUMAN

<400> 70

ccgaggtgag c 11

<210> 71
<211> 11
<212> DNA
<213> HUMAN

<400> 71
tggaggtacc a 11

<210> 72
<211> 11
<212> DNA
<213> HUMAN

<400> 72
ggaaggtcag t 11

<210> 73
<211> 11
<212> DNA
<213> HUMAN

<400> 73
agcaggtggg c 11

<210> 74
<211> 11
<212> DNA
<213> HUMAN

<400> 74
gccaggtaca g 11

<210> 75
<211> 11
<212> DNA
<213> HUMAN

<400> 75
tgctggtgag t 11

<210> 76
<211> 11
<212> DNA
<213> HUMAN

<400> 76
atacagggga t 11

<210> 77
<211> 11
<212> DNA
<213> HUMAN

<400> 77
atacagggga t 11

<210> 78
<211> 11
<212> DNA
<213> HUMAN

<400> 78
ccccaggcga c 11

<210> 79
<211> 11
<212> DNA
<213> HUMAN

<400> 79
acgcagtgca a 11

<210> 80
<211> 11
<212> DNA
<213> HUMAN

<400> 80
tttcagatcc a 11

<210> 81
<211> 11
<212> DNA
<213> HUMAN

<400> 81
ccccaggagg g 11

<210> 82
<211> 11
<212> DNA
<213> HUMAN

<400> 82
tcacaggctc a 11

<210> 83
<211> 11
<212> DNA
<213> HUMAN

<400> 83
ccctagctcc a 11

<210> 84
<211> 11
<212> DNA
<213> HUMAN

<400> 84
ctccagtcca g 11

<210> 85
<211> 12
<212> DNA
<213> HUMAN

<400> 85
tcgcaggtga ca 12

<210> 86

<211> 11
<212> DNA
<213> HUMAN

<400> 86
acacagaagg g 11

<210> 87
<211> 377
<212> PRT
<213> HUMAN

<400> 87
Gln Arg Leu Pro Arg Met Gln Glu Asp Ser Pro Leu Gly Gly Gly Ser
1 5 10 15

Ser Gly Glu Asp Asp Pro Leu Gly Glu Glu Asp Leu Pro Ser Glu Glu
20 25 30

Asp Ser Pro Arg Glu Glu Asp Pro Pro Gly Glu Glu Asp Leu Pro Gly
35 40 45

Glu Glu Asp Leu Pro Gly Glu Glu Asp Leu Pro Glu Val Lys Pro Lys
50 55 60

Ser Glu Glu Glu Gly Ser Leu Lys Leu Glu Asp Leu Pro Thr Val Glu
65 70 75 80

Ala Pro Gly Asp Pro Gln Glu Pro Gln Asn Asn Ala His Arg Asp Lys
85 90 95

Glu Gly Asp Asp Gln Ser His Trp Arg Tyr Gly Gly Asp Pro Pro Trp
100 105 110

Pro Arg Val Ser Pro Ala Cys Ala Gly Arg Phe Gln Ser Pro Val Asp
115 120 125

Ile Arg Pro Gln Leu Ala Ala Phe Cys Pro Ala Leu Arg Pro Leu Glu
130 135 140

Leu Leu Gly Phe Gln Leu Pro Pro Leu Pro Glu Leu Arg Leu Arg Asn
145 150 155 160

Asn Gly His Ser Val Gln Leu Thr Leu Pro Pro Gly Leu Glu Met Ala
165 170 175

Leu Gly Pro Gly Arg Glu Tyr Arg Ala Leu Gln Leu His Leu His Trp
180 185 190

Gly Ala Ala Gly Arg Pro Gly Ser Glu His Thr Val Glu Gly His Arg
195 200 205

Phe Pro Ala Glu Ile His Val Val His Leu Ser Thr Ala Phe Ala Arg
210 215 220

Val Asp Glu Ala Leu Gly Arg Pro Gly Gly Leu Ala Val Leu Ala Ala
225 230 235 240

Phe Leu Glu Glu Gly Pro Glu Glu Asn Ser Ala Tyr Glu Gln Leu Leu
245 250 255

Ser Arg Leu Glu Glu Ile Ala Glu Glu Gly Ser Glu Thr Gln Val Pro
260 265 270

Gly Leu Asp Ile Ser Ala Leu Leu Pro Ser Asp Phe Ser Arg Tyr Phe
275 280 285

Gln Tyr Glu Gly Ser Leu Thr Thr Pro Pro Cys Ala Gln Gly Val Ile
290 295 300

Trp Thr Val Phe Asn Gln Thr Val Met Leu Ser Ala Lys Gln Leu His
305 310 315 320

Thr Leu Ser Asp Thr Leu Trp Gly Pro Gly Asp Ser Arg Leu Gln Leu
325 330 335

Asn Phe Arg Ala Thr Gln Pro Leu Asn Gly Arg Val Ile Glu Ala Ser
340 345 350

Phe Pro Ala Gly Val Asp Ser Ser Pro Arg Ala Ala Glu Pro Val Gln
355 360 365

Leu Asn Ser Cys Leu Ala Ala Gly Asp
370 375

<210> 88
<211> 34
<212> DNA
<213> HUMAN

<400> 88

tagacagatc tacgatggct cccctgtgcc ccag 34

<210> 89
<211> 34
<212> DNA
<213> HUMAN

<400> 89
attcctctag acagttaccg gctccccctc agat 34

<210> 90
<211> 3532
<212> DNA
<213> HUMAN

<220>
<221> misc_feature which includes the MN gene promoter
<222> (1)..(3532)
<223> region including the transcription initiation site (nucleotide 3507 of SEQ ID NO: 5 and of Figures 2A-2F) as determined by RNase protection assay, which region is inclusive of the MN gene promoter, and corresponds to nucleotide 7 to nucleotide 3538 of SEQ ID NO: 5 and of Figures 2A-2F.

<220>
<221> unsure what base is at position 1968
<222> (1968)
<223> unsure of the base at position 1968, which is the same unknown base at position 1974 of SEQ ID NO: 5 (the full-length MN genomic sequence), position 1968 of SEQ ID NO: 58 and position 647 of SEQ ID NO: 110. That unknown base is in the region that includes the transcription initiation site (nucleotide 3507 of SEQ ID NO: 5 and of Figures 2A-2F) as determined by RNase protection assay, which region is inclusive of the MN gene promoter.

<400> 90
tgttgactcg tgaccttacc cccaaccctg tgctctctga aacatgagct gtgtccactc 60
agggttaaat ggattaaggg cggtgcaaga tgtgctttgt taaacagatg cttgaaggca 120
gcatgctcgt taagagtcat caccaatccc taatctcaag taatcaggga cacaaacact 180
gcggaaggcc gcagggtcct ctgcctagga aaaccagaga cctttgttca cttgtttatc 240
tgaccttccc tccactattg tccatgaccc tgccaaatcc ccctctgtga gaaacaccca 300
agaattatca ataaaaaaat aaatttaaaa aaaaaataca aaaaaaaaaa aaaaaaaaaa 360
aaaagactta cgaatagtta ttgataaatg aatagctatt ggtaaagcca agtaaatgat 420
catattcaaa accagacggc catcatcaca gctcaagtct acctgatttg atctctttat 480
cattgtcatt ctttggattc actagattag tcatcatcct caaaattctc ccccaagttc 540

taattacgtt ccaaacattt aggggttaca tgaagcttga acctactacc ttctttgctt 600
ttgagccatg agttgtagga atgatgagtt tacaccttac atgctgggga ttaatttaaa 660
ctttacctct aagtcagttg ggtagccttt ggcttatttt tgtagctaat tttgtagtta 720
atggatgcac tgtgaatctt gctatgatag ttttcctcca cactttgcca ctaggggtag 780
gtaggtactc agttttcagt aattgcttac ctaagaccct aagccctatt tctcttgtac 840
tggcctttat ctgtaatatg ggcatattta atacaatata atttttggag tttttttgtt 900
tgtttgtttg tttgtttttt tgagacggag tcttgcatct gtcatgccca ggctggagta 960
gcagtggtgc catctcggct cactgcaagc tccacctccc gagttcacgc cattttcctg 1020
cctcagcctc ccgagtagct gggactacag gcgcccgcca ccatgcccgg ctaatttttt 1080
gtatttttgg tagagacggg gtttcaccgt gttagccaga atggtctcga tctcctgact 1140
tcgtgatcca cccgcctcgg cctcccaaag ttctgggatt acaggtgtga gccaccgcac 1200
ctggccaatt ttttgagtct tttaaagtaa aaatatgtct tgtaagctgg taactatggt 1260
acatttcctt ttattaatgt ggtgctgacg gtcatatagg ttcttttgag tttggcatgc 1320
atatgctact ttttgcagtc ctttcattac atttttctct cttcatttga agagcatgtt 1380
atatctttta gcttcacttg gcttaaaagg ttctctcatt agcctaacac agtgtcattg 1440
ttggtaccac ttggatcata agtggaaaaa cagtcaagaa attgcacagt aatacttgtt 1500
tgtaagaggg atgattcagg tgaatctgac actaagaaac tcccctacct gaggtctgag 1560
attcctctga cattgctgta tataggcttt tcctttgaca gcctgtgact gcggactatt 1620
tttcttaagc aagatatgct aaagttttgt gagccttttt ccagagagag gtctcatatc 1680
tgcatcaagt gagaacatat aatgtctgca tgtttccata tttcaggaat gtttgcttgt 1740
gttttatgct tttatataga cagggaaact tgttcctcag tgacccaaaa gaggtgggaa 1800
ttgttattgg atatcatcat tggcccacgc tttctgacct tggaaacaat taagggttca 1860
taatctcaat tctgtcagaa ttggtacaag aaatagctgc tatgtttctt gacattccac 1920
ttggtaggaa ataagaatgt gaaactcttc agttggtgtg tgtccctngt ttttttgcaa 1980
tttccttctt actgtgttaa aaaaaagtat gatcttgctc tgagaggtga ggcattctta 2040
atcatgatct ttaaagatca ataatataat cctttcaagg attatgtctt tattataata 2100
aagataattt gtctttaaca gaatcaataa tataatccct taaaggatta tatctttgct 2160
gggcgcagtg gctcacacct gtaatcccag cactttgggt ggccaaggtg gaaggatcaa 2220
atttgcctac ttctatatta tcttctaaag cagaattcat ctctcttccc tcaatatgat 2280
gatattgaca gggtttgccc tcactcacta gattgtgagc tcctgctcag ggcaggtagc 2340
gttttttgtt tttgtttttg tttttctttt ttgagacagg gtcttgctct gtcacccagg 2400
ccagagtgca atggtacagt ctcagctcac tgcagcctca accgcctcgg ctcaaaccat 2460
catcccattt cagcctcctg agtagctggg actacaggca catgccatta cacctggcta 2520
atttttttgt atttctagta gagacagggt ttggccatgt tgcccgggct ggtctcgaac 2580
tcctggactc aagcaatcca cccacctcag cctcccaaaa tgagggaccg tgtcttattc 2640
atttccatgt ccctagtcca tagcccagtg ctggacctat ggtagtacta aataaatatt 2700
tgttgaatgc aatagtaaat agcatttcag ggagcaagaa ctagattaac aaaggtggta 2760
aaaggtttgg agaaaaaaat aatagtttaa tttggctaga gtatgaggga gagtagtagg 2820
agacaagatg gaaaggtctc ttgggcaagg ttttgaagga agttggaagt cagaagtaca 2880
caatgtgcat atcgtggcag gcagtgggga gccaatgaag gcttttgagc aggagagtaa 2940
tgtgttgaaa aataaatata ggttaaacct atcagagccc ctctgacaca tacacttgct 3000
tttcattcaa gctcaagttt gtctcccaca tacccattac ttaactcacc ctcgggctcc 3060
cctagcagcc tgccctacct ctttacctgc ttcctggtgg agtcagggat gtatacatga 3120
gctgctttcc ctctcagcca gaggacatgg ggggccccag ctcccctgcc tttccccttc 3180
tgtgcctgga gctgggaagc aggccagggt tagctgaggc tggctggcaa gcagctgggt 3240
ggtgccaggg agagcctgca tagtgccagg tggtgccttg ggttccaagc tagtccatgg 3300

ccccgataac cttctgcctg tgcacacacc tgcccctcac tccaccccca tcctagcttt 3360
ggtatggggg agagggcaca gggccagaca aacctgtgag actttggctc catctctgca 3420
aaagggcgct ctgtgagtca gcctgctccc ctccaggctt gctcctcccc cacccagctc 3480
tcgtttccaa tgcacgtaca gcccgtacac accgtgtgct gggacacccc ac 3532

<210> 91
<211> 204
<212> DNA
<213> HUMAN

<400> 91
cctgcccctc actccacccc catcctagct ttggtatggg ggagagggca cagggccaga 60
caaacctgtg agactttggc tccatctctg caaaagggcg ctctgtgagt cagcctgctc 120
ccctccaggc ttgctcctcc cccacccagc tctcgtttcc aatgcacgta cagcccgtac 180
acaccgtgtg ctgggacacc ccac 204

<210> 92
<211> 132
<212> DNA
<213> HUMAN

<400> 92
ggatcctgtt gactcgtgac cttaccccca accctgtgct ctctgaaaca tgagctgtgt 60
gcactcaggg ttaaatggat taagggcggt gcaagatgtg ctttgttaaa cagatgcttg 120
aaggcagcat gc 132

<210> 93
<211> 275
<212> DNA
<213> HUMAN

<400> 93
gcatagtgcc aggtggtgcc ttgggttcca agctagtcca tggccccgat aaccttctgc 60
ctgtgcacac acctgccccc cactccaccc ccatcctagc tttggtatgg gggagagggc 120
acagggccag acaaacctgt gagactttgg ctccatctct gcaaaagggc gctctgtgag 180
tcagcctgct cccctccagg cttgctcctc ccccacccag ctctcgtttc caatgcacgt 240
acagcccgta cacaccgtgt gctgggacac cccac 275

<210> 94
<211> 89
<212> DNA
<213> HUMAN

<400> 94
ctgctcccct ccaggcttgc tcctccccca cccagctctc gtttccaatg cacgtacagc 60
ccgtacacac cgtgtgctgg gacacccca 89

<210> 95
<211> 61
<212> DNA
<213> HUMAN

<400> 95
cacccagctc tcgtttccaa tgcacgtaca gcccgtacac accgtgtgct gggacacccc 60
a 61

<210> 96
<211> 116
<212> DNA
<213> HUMAN

<400> 96
acctgcccct cactccaccc ccatcctagc tttggtatgg gggagagggc acagggccag 60
acaaacctgt gagactttgg ctccatctct gcaaaagggc gctctgtgag tcagcc 116

<210> 97
<211> 36
<212> PRT
<213> HUMAN

<400> 97
Gly Glu Glu Asp Leu Pro Ser Glu Glu Asp Ser Pro Arg Glu Glu Asp
1 5 10 15

Pro Pro Gly Glu Glu Asp Leu Pro Gly Glu Glu Asp Leu Pro Gly Glu
20 25 30

Glu Asp Leu Pro
35

<210> 98
<211> 6
<212> PRT
<213> HUMAN

<400> 98
Gly Glu Glu Asp Leu Pro
1 5

<210> 99
<211> 4
<212> PRT
<213> HUMAN

<400> 99
Glu Glu Asp Leu
1

<210> 100
<211> 5
<212> PRT
<213> HUMAN

<400> 100
Glu Glu Asp Leu Pro
1 5

<210> 101
<211> 6
<212> PRT
<213> HUMAN

<400> 101
Glu Asp Leu Pro Ser Glu
1 5

<210> 102
<211> 7
<212> PRT
<213> HUMAN

<400> 102
Glu Glu Asp Leu Pro Ser Glu
1 5

<210> 103

<211> 6
<212> PRT
<213> HUMAN

<400> 103
Asp Leu Pro Gly Glu Glu
1 5

<210> 104
<211> 22
<212> PRT
<213> HUMAN

<400> 104
Gly Gly Ser Ser Gly Glu Asp Asp Pro Leu Gly Glu Glu Asp Leu Pro
1 5 10 15

Ser Glu Glu Asp Ser Pro
20

<210> 105
<211> 25
<212> PRT
<213> HUMAN

<400> 105
Gly Glu Glu Asp Leu Pro Ser Glu Glu Asp Ser Pro Arg Glu Glu Asp
1 5 10 15

Pro Pro Gly Glu Glu Asp Leu Pro Gly
20 25

<210> 106
<211> 24
<212> PRT
<213> HUMAN

<400> 106
Glu Asp Pro Pro Gly Glu Glu Asp Leu Pro Gly Glu Glu Asp Leu Pro
1 5 10 15

Gly Glu Glu Asp Leu Pro Glu Val
20

<210> 107
<211> 7
<212> PRT
<213> HUMAN

<400> 107
Gly Glu Thr Arg Ala Pro Leu
1 5

<210> 108
<211> 7
<212> PRT
<213> HUMAN

<400> 108
Gly Glu Thr Arg Glu Pro Leu
1 5

<210> 109
<211> 7
<212> PRT
<213> HUMAN

<400> 109
Gly Gln Thr Arg Ser Pro Leu
1 5

<210> 110
<211> 1247
<212> DNA
<213> HUMAN

<220>
<221> misc_feature
<222> (1)..(1247)
<223> region 5' to the transcription initiation site as determined by RNase protection assay (nucleotide 3507 of SEQ ID NO: 5 and of Figures 2A-2F) in which an activating element is localized, which region corresponds to nucleotide 1328 to nucleotide 2574 of SEQ ID NO: 5 and of Figures 2A-2F.

<220>
<221> unsure what base is at position 647

<222> (647)
<223> unsure of the base at position 647, which is the same unknown base as that at position 1974 of SEQ ID NO: 5, and as that at position 1968 of SEQ ID NOS: 58 and 90. That unknown base at position 647 is in a region in which an activating element is localized and is 5' to the transcription initiation site.

<400> 110
tatgctactt tttgcagtcc tttcattaca tttttctctc ttcatttgaa gagcatgtta 60
tatcttttag cttcacttgg cttaaaaggt tctctcatta gcctaacaca gtgtcattgt 120
tggtaccact tggatcataa gtggaaaaac agtcaagaaa ttgcacagta atacttgttt 180
gtaagaggga tgattcaggt gaatctgaca ctaagaaact cccctacctg aggtctgaga 240
ttcctctgac attgctgtat ataggctttt cctttgacag cctgtgactg cggactattt 300
ttcttaagca agatatgcta aagttttgtg agccttttc cagagagagg tctcatatct 360
gcatcaagtg agaacatata atgtctgcat gtttccatat ttcaggaatg tttgcttgtg 420
ttttatgctt ttatatagac agggaaactt gttcctcagt gacccaaaag aggtgggaat 480
tgttattgga tatcatcatt ggcccacgct ttctgacctt ggaaacaatt aagggttcat 540
aatctcaatt ctgtcagaat tggtacaaga aatagctgct atgtttcttg acattccact 600
tggtaggaaa taagaatgtg aaactcttca gttggtgtgt gtccctngtt tttttgcaat 660
ttccttctta ctgtgttaaa aaaaagtatg atcttgctct gagaggtgag gcattcttaa 720
tcatgatctt taaagatcaa taatataatc ctttcaagga ttatgtcttt attataataa 780
agataatttg tctttaacag aatcaataat ataatccctt aaaggattat atctttgctg 840
ggcgcagtgg ctcacacctg taatcccagc actttgggtg gccaaggtgg aaggatcaaa 900
tttgcctact tctatattat cttctaaagc agaattcatc tctcttccct caatatgatg 960
atattgacag ggtttgccct cactcactag attgtgagct cctgctcagg gcaggtagcg 1020
ttttttgttt ttgtttttgt ttttcttttt tgagacaggg tcttgctctg tcacccaggc 1080
cagagtgcaa tggtacagtc tcagctcact gcagcctcaa ccgcctcggc tcaaaccatc 1140
atcccatttc agcctcctga gtagctggga ctacaggcac atgccattac acctggctaa 1200
ttttttttgta tttctagtag agacagggtt tggccatgtt gcccggg 1247

<210> 111
<211> 17
<212> DNA
<213> HUMAN

<400> 111
ctctgtgagt cagcctg 17

<210> 112
<211> 23
<212> DNA
<213> HUMAN

<400> 112

aggcttgctc ctcccccacc cag 23

<210> 113
<211> 18
<212> DNA
<213> HUMAN

<400> 113
agactttggc tccatctc 18

<210> 114
<211> 20
<212> DNA
<213> HUMAN

<400> 114
cactccaccc ccatcctagc 20

<210> 115
<211> 26
<212> DNA
<213> HUMAN

<400> 115
gggagagggc acagggccag acaaac 26

<210> 116
<211> 20
<212> PRT
<213> HUMAN

<400> 116
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
1 5 10 15

Gly Gly Gly Ser
20

IN THE CLAIMS

Please cancel Claims 1-21, 28 and 29. Please amend the claims as follows.

Please replace Claim 22 with the following new Claim 22:

22. (Amended) An anti-idiotype antibody to an antibody which specifically binds to an MN protein, wherein said MN protein is encoded by a nucleic acid selected from the group consisting of:

(a) SEQ ID NO: 1;

(b) polynucleotides that hybridize under stringent conditions to SEQ ID NO: 1's complement; and

(c) polynucleotides that differ from SEQ ID NO: 1 or from the polynucleotide sequences of (b) due to the degeneracy of the genetic code.

Please replace Claim 23 with the following new Claim 23:

23. (Amended) An anti-idiotype antibody according to Claim 22, wherein said antibody that is specific for said MN protein, is either the M75 monoclonal antibody secreted from the hybridoma VU-M75, which was deposited at the American Type Culture Collection under ATCC No. HB 11128, or the MN12 monoclonal antibody that is secreted from the hybridoma MN

12.2.2, which was deposited at the American Type Culture Collection under ATCC No. HB 11647.

Please add new Claims 30-52.

30. An anti-idiotype antibody to an antibody which specifically binds to an MN polypeptide, wherein said MN polypeptide is encoded by a nucleic acid that comprises a polynucleotide containing at least 29 nucleotides, said nucleic acid being selected from the group consisting of:

(a) SEQ ID NO: 1;

(b) polynucleotides that hybridize under stringent conditions to SEQ ID NO: 1's complement; and

(c) polynucleotides that differ from SEQ ID NO: 1 or from the polynucleotide sequences of (b) due to the degeneracy of the genetic code.

31. The anti-idiotype antibody according to Claim 30, wherein said antibody that is specific to said MN polypeptide is either the M75 monoclonal antibody secreted from the hybridoma VU-M75, which was deposited at the American Type Culture Collection under ATCC No. HB 11128, or the MN12 monoclonal antibody that is secreted from the hybridoma MN 12.2.2, which was

deposited at the American Type Culture Collection under ATCC No. HB 11647.

32. An anti-anti-idiotype antibody to the anti-idiotype antibody according to Claim 30.

33. An anti-anti-idiotype antibody to the anti-idiotype antibody according to Claim 31.

34. An anti-anti-idiotype antibody according to Claim 32 which is polyclonal.

35. An anti-anti-idiotype antibody according to Claim 33 which is polyclonal.

36. The anti-idiotype antibody according to Claim 30 wherein said nucleic acid comprises a polynucleotide containing at least 50 nucleotides.

37. The anti-idiotype antibody according to Claim 30 wherein said polynucleotide comprises at least 100 nucleotides.

38. The anti-idiotype antibody according to Claim 30 wherein said nucleic acid comprises a polynucleotide containing at least 150 nucleotides.

39. An anti-anti-idiotype antibody to the anti-idiotype antibody according to Claim 36.

40. An anti-anti-idiotype antibody to the anti-idiotype antibody according to Claim 37.

41. An anti-anti-idiotype antibody to the anti-idiotype antibody according to Claim 38.

42. An anti-idiotype antibody to an antibody which specifically binds to an MN polypeptide, wherein said MN polypeptide is encoded by a nucleic acid that comprises a polynucleotide containing at least 25 nucleotides, said nucleic acid being selected from the group consisting of:

(a) SEQ ID NO: 1;

(b) polynucleotides that hybridize under stringent conditions to SEQ ID NO: 1's complement; and

(c) polynucleotides that differ from SEQ ID NO: 1 or from the polynucleotide sequences of (b) due to the degeneracy of the genetic code.

43. The anti-idiotype antibody according to Claim 42 wherein said nucleic acid comprises a polynucleotide containing at least 27 nucleotides.

44. An anti-anti-idiotype antibody to the anti-idiotype antibody according to Claim 42.

45. An anti-anti-idiotype antibody to the anti-idiotype antibody according to Claim 43.

46. The anti-idiotype antibody according to Claim 22 wherein said MN protein is encoded by SEQ ID NO: 1 or by a fragment of SEQ ID NO: 1.

47. The anti-idiotype antibody according to Claim 30 wherein said MN polypeptide is encoded by a fragment of SEQ ID NO: 1.

48. The anti-idiotype antibody according to Claim 42 wherein said MN polypeptide is encoded by a fragment of SEQ ID NO: 1.

49. An anti-anti-idiotype antibody to the anti-idiotype antibody according to Claim 46.

50. An anti-anti-idiotype antibody to the anti-idiotype antibody according to Claim 47.

51. An anti-anti-idiotype antibody to the anti-idiotype antibody according to Claim 48.

52. The anti-idiotype antibody according to Claim 22 wherein said stringent hybridization conditions comprise 50% formamide at 42 degrees C.

REMARKS

To assist in the examination of this application and as required by 37 CFR 1.121, enclosed herewith as Appendix 1 is a marked up version of the changes made to the specification and claims to indicate how the previous version of the specification has been modified to produce the clean replacement paragraphs.

The modifications are indicated by underlining and in bold type for additions, and by strikeouts for deletions. Also enclosed as Appendix 2 is a clean set of all the claims now pending the accordance with 37 CFR 1.121(c)(3).

Specification

The Specification has been amended to claim priority from the parent, grandparent, great-grandparent, great-great grandparent and great-great-great-grandparent applications and to update the status of those priority applications. The Specification has also been amended to correct a number of typographical/proofreading errors.

The Specification at page 3 has been amended to correct a typographical/proofreading error in the year of publication of an article by Zavada et al., in the International Journal of Cancer. The Specification has also been amended to correct other obvious typographical/proofreading errors.

The Specification has been amended in Table 1, line 5, page 34 in order to replace "Intron" with "Exon". Page 33, lines 20-25 reads as follows:

> Exon-Intron Structure of Complete MN Genomic Region
>
> The complete sequence of the overlapping clones contains 10,898 bp (SEQ ID NO: 5). Figure 5 depicts the organization of the

> human MN gene, showing the location of all 11 exons as well as the 2 upstream and 6 intronic Alu repeat elements. All the exons are small, ranging from 27 to 191 bp, with the exception of the first exon which is 445 bp. The intron sizes range from 89 to 1400 bp.

[Emphasis added.] As the above quote shows, the MN gene contains 11 exons, and that the first exon contains 445 base pairs. The top section of Table 1 depicts 11 regions wherein the first region contains 445 base pairs. Further, the same Table 1 can be found in many of the issued MN patents including U.S. Patent 5,972,353. Table 1 (at column 18) of U.S. Patent No. 5,972,353 reads "Exon" on its fifth line. Applicants respectfully submit that the amendment at page 34 of the instant application corrects a typographical, proofreading error that would be obvious to those of skill in the art.

Claims

Applicants have canceled Claims 1-21, 28 and 29 in that the instant application is a divisional of its parent application - U.S. Serial No. 09/178,115. The parent application was subject to a 5-way Election/Restriction Requirement mailed from the U.S. Patent and Trademark Office (PTO) on June 21, 2000. The claims of the instant application are based upon the Group II claims of that Election/Restriction Requirement ["II. Claims 9-11 and 22-

27, drawn to a MN-specific antibody, classified in class 530, subclass 387.1."]

Appendix 1 shows the amendments made to Claims 22-27 of the parent application. Applicants respectfully submit that those amendments and the addition of new Claims 30-52 are made to point out with more particularity and clarity the subject matter regarded by the Applicants as their invention, and that no new subject matter has been added by those amendments and new claims.

Support in the Specification concerning anti-idiotype antibodies to MN-specific antibodies and anti-anti-idiotype antibodies to such anti-idiotype antibodies can be found at least at page 12, line 29 to page 13, line 31; at page 15, lines 24-33; at page 75, line 11 to page 76, line 21; at page 81, lines 27-32; and at page 122, lines 9-12.

The amendment to Claim 22 specifies with particularity and clarity the term "MN-specific antibody," and that terminology reflected in new Claims 30-52 is supported throughout the Specification, e.g., at least at page 7, line 12 to page 15, line 14; more specifically, e.g., at least at page 7, lines 12-20, at page 9, lines 18-24, at page 10, lines 15-24, at page 12, lines 29-31, at page 13, lines 12-18, at page 13, lines 27-31 and at page 14, lines 4-5.

Stringent hybridization conditions, to which independent Claims 22, 30 and 42 refer, are described and exemplified in the Specification at least at page 60, line 6 to page 61, line 10. Specifically, the condition of "50% formamide at 42 degrees C" of new Claim 52 is supported at least at page 60, lines 13-19, at page 7, lines 12-21 and at page 8, lines 7-20.

The terms "protein" and "polypeptide" of the instant claims are defined in the Specification at page 53, lines 7-10. Whereas "polypeptide" is composed of "50 or less amino acids," "a protein" is "composed of more than 50 amino acids."

The phrases concerning "a polynucleotide containing" different numbers of nucleotides -- "at least 29 nucleotides" (Claim 30), "at least 50 nucleotides" (Claim 36), "at least 100 nucleotides" (Claim 37), "at least 150 nucleotides (Claim 38), "at least 25 nucleotides" (Claim 42), and "at least 27 nucleotides" (Claim 43) --are supported in the Specification at least at page 8, lines 3-6, at page 8, line 30 to page 9, line 1, and at page 60, lines 26-29.

Applicants respectfully conclude that no new matter has been entered by the above amendments and new Claims 30-52.

CONCLUSION

Applicants respectfully request that the above amendments to Claims 22-27 of the parent application and and new Claims 30-52 be entered into the instant application. Applicants respectfully submit that the claims as presented are in condition for allowance, and earnestly request their prompt allowance. If the undersigned Attorney for the Applicants can be of any assistance in regard to this <u>Preliminary Amendment</u>, she can be reached at (415) 981-2034.

Respectfully submitted,

Leona L. Lauder
Attorney for Applicants
Registration No. 30,863

Dated: September 27, 2001